{"gene":"ICOS","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":1999,"finding":"ICOS is a homodimeric T-cell-specific cell-surface protein (Mr 55K-60K) that is de novo induced on T-cell surfaces upon activation (unlike constitutively expressed CD28), co-stimulates T-cell proliferation, lymphokine secretion, and B-cell help, superinduces IL-10 but does not upregulate IL-2, and is highly expressed on tonsillar germinal-centre T cells.","method":"Molecular cloning, flow cytometry, functional co-stimulation assays, immunohistochemistry","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — original discovery paper with multiple orthogonal methods, highly cited, replicated across labs","pmids":["9930702"],"is_preprint":false},{"year":1999,"finding":"ICOS (murine homologue) binds specifically to B7-related protein-1 (B7RP-1/ICOSL), a B7-family ligand expressed on B cells and macrophages; this receptor-ligand pair does not cross-interact with CD28, B7-1, or B7-2, defining a distinct co-stimulatory pathway.","method":"Receptor-ligand binding assays, fusion-protein co-stimulation, transgenic mouse overexpression","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding and functional co-stimulation assays, replicated by multiple labs","pmids":["10617205"],"is_preprint":false},{"year":2001,"finding":"ICOS is essential in vivo for T-cell-dependent B-cell responses: ICOS-deficient mice show severely impaired germinal centre formation, defective immunoglobulin class switching (including IgE), reduced IL-4 production by primed T cells, and deficient T-B cell interactions.","method":"Gene-targeted ICOS-knockout mouse generation and phenotypic characterization, in vitro restimulation assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotypes, replicated by independent groups","pmids":["11343123"],"is_preprint":false},{"year":2000,"finding":"ICOS expression is upregulated by CD28 co-stimulation (CD80/CD86-dependent) and promotes CD4+ T-cell proliferation and production of IFN-γ, IL-4, and IL-10 but not IL-2; blocking ICOS:B7h interaction shifts differentiation away from Th2 toward Th1.","method":"Anti-mouse ICOS mAbs and ICOS-Ig fusion protein blockade, bead-based co-stimulation assays, TCR-transgenic T-cell differentiation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays, replicated findings","pmids":["11046032"],"is_preprint":false},{"year":2003,"finding":"Homozygous deletion of the ICOS gene in humans causes adult-onset common variable immunodeficiency with reduced naive, switched, and memory B cells, demonstrating ICOS is critical for T-cell help for late B-cell differentiation, class-switching, and memory B-cell generation.","method":"Genetic analysis (homozygous deletion), immunophenotyping of patient T and B cells","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — human loss-of-function with defined immunological phenotype, highly cited","pmids":["12577056"],"is_preprint":false},{"year":2003,"finding":"ICOS signals through PI3K (recruitment to ICOS cytoplasmic domain upon cross-linking) and enhances TCR-proximal signals including ZAP-70, zeta, Vav phosphorylation and ERK, JNK, and p38 MAP kinase activation; PI3K activity is required for ERK/JNK activation and IL-4/IL-10 secretion.","method":"ICOS cross-linking, kinase activity assays, PI3K inhibitors, phosphorylation western blots in Th2 clones","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical assays with inhibitors and mutagenesis, consistent with multiple studies","pmids":["12594849"],"is_preprint":false},{"year":2000,"finding":"Human ICOS is a 55-60 kDa homodimer with N-glycosylated subunits of 27 and 29 kDa; it requires PMA plus ionomycin for full induction, is sensitive to cyclosporin A, does not bind B7-1 or B7-2, and maps to chromosome 2q33-34. CD28/B7 but not CD40L/CD40 pathway is critically involved in ICOS induction by APCs. ICOS co-stimulation prevents apoptosis of pre-activated T cells and superinduces IL-10.","method":"Biochemical characterization, flow cytometry, cytokine assays, chromosomal mapping","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical and functional methods in a single study","pmids":["11169414"],"is_preprint":false},{"year":2001,"finding":"CTLA-4 ligation blocks ICOS co-stimulation both indirectly (by preventing ICOS surface expression on resting cells) and directly (by blocking ICOS-mediated IL-4, IL-10, IL-13 induction on pre-activated cells); exogenous IL-2 overcomes both mechanisms and is required for sustained ICOS-costimulated T-cell growth.","method":"Anti-CD3/anti-ICOS/anti-CTLA-4 bead stimulation, cytokine ELISA, IL-2 neutralization and addition experiments","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays with defined mechanistic dissection","pmids":["11290772"],"is_preprint":false},{"year":2006,"finding":"ICOS expression is transcriptionally controlled by the Fyn-calcineurin-NFATc2 axis and a separate MEK2-ERK1/2 pathway; NFATc2 binds the icos promoter in vivo and this binding is reduced in Fyn-/- T cells; ectopic NFATc2 or constitutively active MEK2 transactivates a 288-bp core icos promoter region.","method":"Chemical inhibitors (PP2, U0126, CsA, FK506), luciferase reporter assays, ChIP, Fyn-/- mice","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — promoter reporter, ChIP, and genetic KO with multiple inhibitors","pmids":["16880206"],"is_preprint":false},{"year":2013,"finding":"ICOS directly drives follicular recruitment of activated T-helper cells by promoting pseudopod formation and persistent T-cell migration at the T-zone/B-follicle border; this requires ICOSL expression by follicular bystander B cells and is independent of ICOSL on dendritic cells or cognate B cells, and does not require Bcl6 as an intermediate.","method":"Two-photon intravital microscopy (dynamic imaging), ICOS-deficient and ICOSL conditional-KO mice, Bcl6 genetic analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — direct live imaging + genetic epistasis in vivo with multiple KO models","pmids":["23619696"],"is_preprint":false},{"year":2015,"finding":"ICOS co-stimulation signals via PI3K to inactivate the transcription factor FOXO1, promoting Tfh cell differentiation; Foxo1 deletion rescues Tfh generation in ICOS-deficient conditions, while enforced nuclear FOXO1 blocks Tfh development even with ICOS overexpression; final GC-Tfh differentiation requires FOXO1 activity.","method":"Foxo1 conditional KO and nuclear-localization knock-in mice, ICOS-deficient mice, flow cytometry, gene expression analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple KO/KI models, mechanistic pathway defined","pmids":["25692700"],"is_preprint":false},{"year":2015,"finding":"ICOS (but not CD28) co-stimulation is exclusively required for maintaining the Tfh phenotype by downregulating the transcription factor Klf2 via Foxo1; Klf2 directly binds to Cxcr5, Ccr7, Psgl-1, and S1pr1 promoters, and low Klf2 levels maintain the Tfh homing receptor pattern and follicular localization.","method":"ICOS blockade in vivo, Klf2 ChIP, conditional KO mice, gene expression and flow cytometry","journal":"Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP, genetic epistasis, ICOS blockade with defined transcriptional mechanism","pmids":["25646266"],"is_preprint":false},{"year":2018,"finding":"The ICOS transmembrane domain (TMD) is required for association with the tyrosine kinase Lck, and this TMD-Lck association is necessary for p85 (PI3K regulatory subunit) recruitment to ICOS and downstream PI3K activation, as well as for costimulation of calcium mobilization; the ICOS cytoplasmic domain alone is insufficient for these functions. TMD-replaced ICOS fails to support Tfh development or GC formation in vivo.","method":"ICOS domain-swap constructs, co-immunoprecipitation, calcium flux assays, Lck co-association, in vivo Tfh/GC analysis","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 1-2 — domain mutagenesis with reconstitution, biochemical co-IP, and in vivo validation","pmids":["30523347"],"is_preprint":false},{"year":2016,"finding":"ICOS potentiates TCR-induced calcium flux by enhancing PLCγ1 activation and actin remodeling (via RhoA and Cdc42 activation); a membrane-proximal cytoplasmic motif is essential for this calcium-signaling function; interruption of actin dynamics impairs calcium flux even with activated PLCγ1.","method":"ICOS cytoplasmic domain mutagenesis knock-in mice, calcium flux assays, PLCγ1 phosphorylation assays, small GTPase activation assays, actin inhibitors","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 1-2 — domain mutagenesis KI mice, biochemical assays with multiple inhibitors","pmids":["27693916"],"is_preprint":false},{"year":2018,"finding":"Peli1 (an E3 ubiquitin ligase) negatively regulates ICOS expression by limiting c-Rel-mediated ICOS transcription; increased ICOS in Peli1-KO T cells enhances PI3K-AKT signaling, suppresses Klf2, and promotes Tfh differentiation.","method":"Mixed bone marrow chimeras, Peli1-KO mice, c-Rel analysis, PI3K-AKT signaling assays, Klf2 reconstitution","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO, rescue experiments, defined signaling pathway","pmids":["33707688"],"is_preprint":false},{"year":2020,"finding":"Crystal structure of the ICOS/ICOS-L complex at 3.3 Å resolution reveals that a central FDPPPF motif and CC' loop residues of ICOS mediate specificity of ICOS-L binding with a distinct receptor orientation compared to CD28/B7; the N110 N-linked glycan of ICOS participates directly in ICOS-L binding.","method":"X-ray crystallography (3.3 Å), binding assays, structural comparison","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional binding validation","pmids":["33033255"],"is_preprint":false},{"year":2018,"finding":"Binding of NUFIP2 to Roquin-1/2 promotes recognition of ICOS mRNA; post-transcriptional repression of human ICOS by Roquin requires two neighboring non-canonical stem-loops in the ICOS 3'-UTR; NUFIP2 binds Roquin directly with high affinity, stabilizing NUFIP2, and acts as a cofactor for cooperative mRNA target recognition.","method":"RNAi screen (~1500 genes), co-immunoprecipitation, RNA-binding assays, ICOS 3'-UTR stem-loop mutagenesis, NUFIP2-Roquin binding assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide screen, direct binding assays, UTR mutagenesis","pmids":["29352114"],"is_preprint":false},{"year":2008,"finding":"In the germinal centre reaction, ICOS signaling acts upstream of CD40 and lymphotoxin beta receptor (LTβR): ICOS activation on T cells induces LTαβ on B cells in vitro; GC B cells from ICOS-/- mice show reduced LTαβ expression; agonistic anti-CD40 restores GC networks and LTαβ on GC B cells in ICOS-/- mice in a LTβR-dependent manner.","method":"ICOS-/- mice, in vitro T-B co-stimulation, agonistic antibody treatment, flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + in vitro and in vivo rescue experiments defining pathway order","pmids":["18250437"],"is_preprint":false},{"year":2021,"finding":"ICOS engagement in tissues (via ICOSL expressed in tissue) promotes establishment but not maintenance of CD8+ tissue-resident memory (Trm) T cells; this function requires ICOS-mediated PI3K signaling (IcosYF/YF knock-in mice show defective Trm generation); ICOS ligation during priming does not determine Trm induction—local tissue ICOS signaling during effector phase is the critical step.","method":"ICOS-/- and IcosYF/YF knock-in mice, Icosl-/- host transfers, ICOS-L blockade, adoptive transfer experiments, flow cytometry","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — multiple KO/KI genetic models with defined PI3K signaling requirement and temporal dissection","pmids":["34932944"],"is_preprint":false},{"year":2018,"finding":"The ICOS intracellular domain (ICD) enhances in vivo persistence of CAR-expressing CD4+ T cells, and a CAR combining ICOS and 4-1BB ICDs shows superior antitumor effects; the membrane-proximal ICD exerts dominant signaling, and optimal function requires the ICOS ICD linked to the ICOS transmembrane domain.","method":"CAR T-cell mouse tumor models, in vivo persistence assays, domain-swap constructs","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 — domain-swap constructs with in vivo functional readouts","pmids":["29321369"],"is_preprint":false},{"year":2018,"finding":"ICOS signaling (via the Tyr181-based PI3K-binding SH2 motif) is required for induction of collagen-induced arthritis including antibody production and expansion of inflammatory T cells, and for maintenance of CIA in an antibody-independent manner; glycolysis inhibition (3-bromopyruvate) ameliorates established CIA, linking ICOS-PI3K signaling to glucose metabolism.","method":"ICOS KO and PI3K-binding motif knock-in mice, collagen-induced arthritis model, glycolysis inhibitor treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — KO and KI genetic dissection with defined signaling motif and metabolic link","pmids":["29581356"],"is_preprint":false},{"year":2000,"finding":"AILIM (rat ICOS ortholog) functions as a lymphocyte adhesion molecule; AILIM-transfected cells aggregate in an AILIM-dependent manner and human thymoma cells bind purified AILIM, suggesting an adhesion function for ICOS beyond co-stimulation.","method":"Cell aggregation assays, AILIM gene transfection, binding assays with purified protein","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding and cell aggregation assays, but single lab with rat ortholog","pmids":["10607749"],"is_preprint":false},{"year":2004,"finding":"ICOS/AILIM signaling induces transendothelial migration and morphological polarization of memory/effector CD4+ T cells (but not naïve or Th2 cells) via interaction with B7h on TNF-α-treated endothelial cells, and is involved in Th1 cell trafficking into peripheral tissues.","method":"Transwell migration assays, T-cell polarization imaging, anti-ICOS/AILIM stimulation, human endothelial cell co-culture","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct functional assays but single lab","pmids":["15339883"],"is_preprint":false},{"year":2012,"finding":"ICOS signaling is required for generation and suppressive function of CD4+CD25+Foxp3+ regulatory T cells that convey respiratory tolerance; ICOS-/- Tregs produce significantly less IL-10 and fail to suppress airway inflammation when transferred to asthmatic recipients.","method":"ICOS-/- mice, anti-ICOSL blocking antibody, adoptive Treg transfer experiments, cytokine assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — two independent genetic/pharmacological approaches with defined functional readout","pmids":["22815292"],"is_preprint":false},{"year":2013,"finding":"ICOS controls Foxp3+ Treg expansion and maintenance during helminth infection; ICOS deficiency increases Treg apoptosis, impairs Treg-specific IL-10 production, and prevents adaptive (Helios-) Treg responses in the intestinal lamina propria, with tissue-specific consequences on type 2 immunity.","method":"ICOS-/- mice infected with H. polygyrus or S. mansoni, flow cytometry, apoptosis assays, IL-10 intracellular staining","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — KO mice with defined Treg-specific functional readouts across two helminth models","pmids":["23319295"],"is_preprint":false},{"year":2005,"finding":"ICOS co-stimulates invariant NKT (iNKT) cell activation; iNKT cells constitutively express ICOS and upregulate it after α-GalCer treatment; blockade of ICOS-ICOSL or ICOS gene knockout substantially inhibits α-GalCer-induced IFN-γ, IL-4 production, cytotoxic activity, and anti-metastatic effects; CD28 and ICOS act independently.","method":"ICOS-/- mice, anti-B7RP-1 mAb blockade, α-GalCer challenge, cytokine assays, cytotoxicity assays","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — KO + pharmacological blockade with multiple functional readouts","pmids":["15629449"],"is_preprint":false},{"year":2008,"finding":"ICOS/ICOSL interaction is required for CD4+ iNKT cell function and homeostatic survival; ICOS-/- and ICOSL-/- mice have significantly fewer CD4+ iNKT cells; ICOS-/- iNKT cells fail to produce IL-4 and IL-13 upon activation and cannot reconstitute airway hyperreactivity; ICOSL-/- environment induces apoptosis of transferred WT iNKT cells.","method":"ICOS-/- and ICOSL-/- mice, adoptive transfer, α-GalCer challenge, apoptosis assays, cytokine assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — dual KO mouse models with adoptive transfer and multiple functional readouts","pmids":["18390727"],"is_preprint":false},{"year":2011,"finding":"ICOS-ICOSL signaling promotes skin wound healing by sustaining inflammatory cell infiltration and cytokine production (especially Th2 cytokines IL-4, IL-6, IL-10) at the wound site; ICOS-/-, ICOSL-/-, and double-KO mice each show equivalent delays in wound healing with suppressed keratinocyte migration, angiogenesis, and granulation tissue; IL-6 (but not IL-4) application restores early healing in KO mice.","method":"ICOS-/-, ICOSL-/-, and double-KO mice, excisional wound model, T-cell transfer/depletion, cytokine rescue experiments","journal":"American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — three genetic KO models + rescue with specific cytokine","pmids":["21925472"],"is_preprint":false},{"year":2015,"finding":"ICOS promotes activation of ILC2s in lungs: B7RP-1 co-culture increases ILC2 cytokine production; blocking ICOS/B7RP-1 interaction abrogates ILC2 expansion and eosinophil influx induced by papain; lung DCs express B7RP-1 and may serve as the ICOSL-expressing partner for ILC2s.","method":"ILC2 purification, B7RP-1-transfected cell co-culture, blocking mAb, papain-challenge mouse model, flow cytometry","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vitro and in vivo blockade, single lab","pmids":["26049110"],"is_preprint":false},{"year":2009,"finding":"ICOS controls effector function (cytokine production and local proliferation) but not trafficking receptor expression (CXCR3, P-selectin ligand) of kidney-infiltrating CD4+ T cells in murine lupus; ICOS-/- MRL(lpr) effector cells migrate normally to CXCL9 but fail to produce inflammatory cytokines and show impaired in-situ proliferation.","method":"Genetic ablation (ICOS-/- MRL/lpr mice), chemokine/receptor flow cytometry, migration assays, cytokine assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — KO with mechanistic dissection of trafficking vs. effector function","pmids":["19299705"],"is_preprint":false},{"year":2021,"finding":"ICOS signaling limits VAT-Treg accumulation and function in visceral adipose tissue via cell-intrinsic PI3K signaling; ICOS-/- mice and PI3K-binding knock-in mice show increased VAT-Treg abundance with elevated VAT-Treg markers, enhanced CCR3-dependent accumulation, reduced adipose inflammation, and improved insulin sensitivity on high-fat diet.","method":"ICOS-/- and IcosYF/YF knock-in mice, high-fat diet model, flow cytometry, CCR3 expression analysis","journal":"Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — dual KO/KI genetic models identifying PI3K-dependent mechanism in metabolic context","pmids":["33881452"],"is_preprint":false},{"year":2019,"finding":"ICOSL (ICOS ligand) on non-immune podocytes contains an RGD motif that allows high-affinity, selective binding to αvβ3 integrin, limiting its activation; ICOSL deficiency in mice increases susceptibility to proteinuria rescued by recombinant ICOSL, revealing a renoprotective, immune-independent function of ICOSL as an endogenous αvβ3-selective antagonist.","method":"RGD motif mutagenesis, integrin binding assays, Icosl-/- mice, proteinuria models, recombinant ICOSL rescue","journal":"Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — RGD mutagenesis, direct binding assays, KO mouse model with rescue","pmids":["30747722"],"is_preprint":false},{"year":2023,"finding":"Intrathecal administration of an ICOS agonist antibody alleviates paclitaxel-induced neuropathic mechanical hypersensitivity in female mice via an IL-10-mediated mechanism in the dorsal root ganglion; blocking IL-10 receptor occludes the analgesic effect; ICOS agonism also reduces astrogliosis and satellite cell gliosis.","method":"Intrathecal ICOS agonist injection, IL-10R blocking antibody, spared nerve injury model, DRG IL-10 quantification, gliosis assessment","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 — defined IL-10 mechanism with receptor blocking, single lab","pmids":["36774519"],"is_preprint":false},{"year":2019,"finding":"Adipocyte-derived exosomal miR-27a-3p targets the ICOS 3'-UTR to suppress ICOS expression on T cells (confirmed by dual-luciferase reporter assay), reducing ICOS+ T-cell proliferation and IFN-γ secretion, providing a mechanism for obesity-associated enhancement of antitumor immunity.","method":"Dual-luciferase reporter assay (miR-27a-3p vs. ICOS 3'-UTR), exosome isolation, flow cytometry, IFN-γ ELISA","journal":"Thoracic cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct 3'-UTR reporter validation, single lab","pmids":["32212417"],"is_preprint":false},{"year":2022,"finding":"During inflammation, ICOSL upregulation on immunofibroblasts (and DCs) enables ICOS+ T-cell binding to induce LTα3 production, which drives chemokine production required for tertiary lymphoid structure (TLS) assembly via TNFRI/II engagement; pharmacological or genetic ICOS/ICOS-L blockade results in defective LTα expression and abrogates TLS formation.","method":"Genetic and pharmacological ICOS/ICOSL blockade, mouse and human tissue analysis, immunofibroblast-T cell co-culture","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic and pharmacological blocking with in vivo and in vitro validation, single primary lab","pmids":["35508704"],"is_preprint":false},{"year":2016,"finding":"ICOS triggering of osteoclast-expressed ICOSL (B7h) by recombinant ICOS-Fc inhibits RANKL-mediated osteoclast differentiation (suppressing NFATc1, DC-STAMP, OSCAR, TRAP, cathepsin K) and reduces bone loss in ovariectomized mice in vivo.","method":"ICOS-Fc treatment of human monocyte-derived osteoclast-like cells, osteolytic activity assays, ovariectomy mouse model","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro differentiation assays plus in vivo bone loss model, single lab","pmids":["27798154"],"is_preprint":false}],"current_model":"ICOS is an activation-induced homodimeric T-cell co-stimulatory receptor that binds specifically to ICOSL (B7RP-1) via a central FDPPPF motif and CC' loop (with N-linked glycan participation), recruits Lck through its transmembrane domain to enable p85/PI3K activation, and signals via PI3K-AKT to inactivate FOXO1 (promoting Tfh differentiation), enhance PLCγ1-dependent calcium flux and actin remodeling (via RhoA/Cdc42), and activate ERK/JNK/p38 MAP kinases; its expression is transcriptionally regulated by Fyn-calcineurin-NFATc2 and MEK-ERK axes and post-transcriptionally repressed by Roquin/NUFIP2-mediated mRNA decay targeting stem-loops in the ICOS 3'-UTR; through these pathways ICOS drives germinal centre formation (upstream of CD40-LTβR), Tfh maintenance via Klf2 downregulation, Treg IL-10 production and suppressive function, CD8+ tissue-resident memory T-cell establishment, and iNKT cell activation, while CTLA-4 and Peli1 (E3 ubiquitin ligase) serve as negative regulators of ICOS signaling."},"narrative":{"teleology":[{"year":1999,"claim":"Identification of ICOS as a novel activation-induced T-cell co-stimulatory receptor established that the CD28 superfamily contained a second, non-redundant co-stimulatory pathway with distinct cytokine output (IL-10 superinduction, no IL-2 upregulation).","evidence":"Molecular cloning, flow cytometry, functional co-stimulation assays, and immunohistochemistry of human tonsil T cells","pmids":["9930702"],"confidence":"High","gaps":["Ligand identity unknown at time of discovery","Signaling pathway downstream of ICOS uncharacterized","Tissue distribution beyond tonsil not fully mapped"]},{"year":2000,"claim":"Discovery of B7RP-1/ICOSL as the exclusive ICOS ligand, and demonstration that ICOS–ICOSL and CD28–B7 systems do not cross-react, defined two parallel but independent co-stimulatory axes in adaptive immunity.","evidence":"Receptor–ligand binding assays and fusion-protein co-stimulation in murine system; additional biochemical characterization of human ICOS homodimer","pmids":["10617205","11169414"],"confidence":"High","gaps":["Structural basis of ligand specificity unknown","ICOS–ICOSL affinity and kinetics not quantified"]},{"year":2001,"claim":"ICOS knockout mice revealed that ICOS is essential in vivo for germinal centre formation, Ig class switching, and T-dependent B-cell responses, while CTLA-4 was shown to antagonize ICOS-mediated cytokine production, establishing a co-stimulatory/co-inhibitory regulatory circuit.","evidence":"ICOS-deficient mouse phenotyping; anti-CTLA-4/anti-ICOS bead stimulation and IL-2 rescue experiments","pmids":["11343123","11290772"],"confidence":"High","gaps":["Downstream signaling intermediates not identified","Mechanism of CTLA-4 suppression of ICOS expression unresolved"]},{"year":2003,"claim":"Human ICOS deficiency was linked to common variable immunodeficiency, and ICOS signaling was shown to proceed through PI3K recruitment and MAP kinase activation, connecting receptor engagement to cytokine gene regulation.","evidence":"Homozygous ICOS deletion in patients with immunophenotyping; ICOS cross-linking with PI3K inhibitors and kinase assays in Th2 clones","pmids":["12577056","12594849"],"confidence":"High","gaps":["PI3K-binding motif on ICOS not mapped","Transcription factors downstream of PI3K not identified"]},{"year":2006,"claim":"Defining the Fyn–calcineurin–NFATc2 and MEK–ERK transcriptional circuits controlling ICOS promoter activity explained how TCR signal strength and co-stimulation regulate ICOS expression levels.","evidence":"ChIP of NFATc2 on icos promoter, luciferase reporters, Fyn−/− T cells, chemical inhibitors","pmids":["16880206"],"confidence":"High","gaps":["Chromatin accessibility and epigenetic regulation of icos locus not addressed","Post-transcriptional regulation not yet characterized"]},{"year":2008,"claim":"Epistasis experiments placed ICOS upstream of CD40 and LTβR in germinal centre network formation, and demonstrated ICOS is required for iNKT cell homeostasis and effector function, broadening ICOS function beyond conventional T cells.","evidence":"ICOS−/− mice with agonistic anti-CD40 rescue; ICOS−/− and ICOSL−/− mice with α-GalCer challenge and adoptive iNKT transfer","pmids":["18250437","18390727"],"confidence":"High","gaps":["Molecular mechanism linking ICOS to LTαβ induction on B cells not defined","iNKT-intrinsic vs. extrinsic ICOS requirement not fully separated"]},{"year":2013,"claim":"Two-photon imaging showed ICOS drives T-cell pseudopod formation and persistent migration at the T–B border via bystander B-cell ICOSL, explaining how ICOS positions T cells for follicular entry independently of Bcl6; separately, ICOS was shown essential for Treg IL-10 production and suppressive function.","evidence":"Intravital two-photon microscopy with ICOS-deficient and ICOSL conditional-KO mice; ICOS−/− Treg transfer in airway tolerance and helminth models","pmids":["23619696","22815292","23319295"],"confidence":"High","gaps":["Cytoskeletal effectors downstream of ICOS mediating pseudopod formation not identified","Whether ICOS-dependent Treg IL-10 operates through PI3K–FOXO1 untested"]},{"year":2015,"claim":"Genetic epistasis established that ICOS signals through PI3K to inactivate FOXO1, which in turn represses Klf2; Klf2 directly controls Tfh homing receptors (CXCR5, CCR7, PSGL1, S1PR1), providing a complete transcriptional pathway from receptor to cell positioning.","evidence":"Foxo1 conditional KO and nuclear-localization KI mice crossed to ICOS−/−; Klf2 ChIP on Tfh target promoters with ICOS blockade","pmids":["25692700","25646266"],"confidence":"High","gaps":["Whether additional transcription factors act in parallel with FOXO1 downstream of ICOS not tested","Kinetics of FOXO1 inactivation upon ICOS ligation not measured"]},{"year":2016,"claim":"A membrane-proximal cytoplasmic motif of ICOS was shown to potentiate calcium signaling via PLCγ1 activation and RhoA/Cdc42-dependent actin remodeling, revealing a PI3K-independent arm of ICOS signaling.","evidence":"ICOS cytoplasmic domain mutagenesis knock-in mice with calcium flux, PLCγ1 phosphorylation, and small GTPase activation assays","pmids":["27693916"],"confidence":"High","gaps":["Identity of the adaptor linking the proximal motif to RhoA/Cdc42 unknown","Relative contribution of calcium vs. PI3K arm to individual T-cell fates not quantified"]},{"year":2018,"claim":"The ICOS transmembrane domain was identified as the site of Lck association, which is prerequisite for p85/PI3K recruitment and downstream Tfh/GC responses, resolving how ICOS activates PI3K despite lacking a classical ITAM; simultaneously, Roquin/NUFIP2-dependent mRNA decay targeting dual stem-loops in the ICOS 3′-UTR was established as the major post-transcriptional brake on ICOS levels, and Peli1 was identified as a transcriptional negative regulator via c-Rel.","evidence":"Domain-swap constructs with co-IP and in vivo Tfh/GC analysis; genome-wide RNAi screen with 3′-UTR mutagenesis; Peli1-KO mice with PI3K-AKT and Klf2 readouts","pmids":["30523347","29352114","33707688"],"confidence":"High","gaps":["Structural basis of TMD–Lck interaction unresolved","How Roquin selects ICOS mRNA over other targets not fully elucidated","Whether Peli1 directly ubiquitinates c-Rel to limit ICOS transcription not shown"]},{"year":2020,"claim":"The crystal structure of the ICOS–ICOSL complex at 3.3 Å revealed that the FDPPPF motif and CC' loop (with N110 glycan) mediate ligand specificity via a binding orientation distinct from CD28–B7, providing a structural rationale for the non-cross-reactivity of these pathways.","evidence":"X-ray crystallography at 3.3 Å with binding-assay validation","pmids":["33033255"],"confidence":"High","gaps":["No structure of full-length ICOS including TMD and cytoplasmic domain","Dynamics of ICOS dimerization and its role in signaling complex assembly not characterized"]},{"year":2021,"claim":"ICOS–PI3K signaling in the tissue effector phase was shown to be required for establishment of CD8+ tissue-resident memory T cells independently of priming, expanding the functional repertoire of ICOS beyond CD4+ T-cell help; in a distinct context, ICOS–PI3K signaling was found to limit visceral adipose tissue Treg accumulation, revealing context-dependent effects on Treg biology.","evidence":"ICOS−/− and IcosYF/YF KI mice with adoptive transfer and temporal ICOSL blockade for Trm; same genetic models on high-fat diet for VAT-Treg analysis","pmids":["34932944","33881452"],"confidence":"High","gaps":["Downstream effectors of PI3K that distinguish Trm establishment from Tfh programming not identified","Whether ICOS limits VAT-Tregs through FOXO1–Klf2 axis specifically not tested"]},{"year":null,"claim":"Key unresolved questions include the structural basis of TMD–Lck association, how ICOS signal strength is integrated across the PI3K and calcium arms to specify distinct T-cell fates (Tfh vs. Treg vs. Trm), and whether ICOS-dependent metabolic reprogramming (glycolysis) is a general feature of its signaling or context-restricted.","evidence":"","pmids":[],"confidence":"High","gaps":["No structure of ICOS TMD–Lck interface","Quantitative signaling model integrating PI3K and PLCγ1 arms absent","Metabolic consequences of ICOS signaling tested only in CIA model"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,5,15]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[21,22]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,4,23,24,25,26]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,10,11,13]}],"complexes":[],"partners":["ICOSL","LCK","PIK3R1","FOXO1","NFATC2","RC3H1","NUFIP2","PELI1"],"other_free_text":[]},"mechanistic_narrative":"ICOS is an activation-induced T-cell co-stimulatory receptor that, through its exclusive ligand ICOSL (B7RP-1), drives germinal centre formation, T follicular helper (Tfh) cell differentiation and maintenance, regulatory T-cell IL-10 production, iNKT cell activation, and CD8+ tissue-resident memory T-cell establishment [PMID:9930702, PMID:11343123, PMID:25692700, PMID:34932944, PMID:18390727, PMID:22815292]. Structurally, ICOS binds ICOSL via a central FDPPPF motif and CC' loop with direct participation of an N110-linked glycan, and its transmembrane domain recruits Lck, which is required for p85/PI3K recruitment to the ICOS cytoplasmic tail; downstream PI3K-AKT signaling inactivates FOXO1 to suppress Klf2, thereby establishing the Tfh homing receptor program, while a membrane-proximal cytoplasmic motif potentiates PLCγ1-dependent calcium flux and RhoA/Cdc42-mediated actin remodeling [PMID:33033255, PMID:30523347, PMID:12594849, PMID:25692700, PMID:25646266, PMID:27693916]. ICOS expression is transcriptionally controlled by Fyn–calcineurin–NFATc2 and MEK–ERK pathways, and post-transcriptionally repressed by Roquin/NUFIP2-mediated decay targeting stem-loops in the ICOS 3′-UTR [PMID:16880206, PMID:29352114]. Homozygous ICOS deletion in humans causes common variable immunodeficiency characterized by defective B-cell class-switching and memory B-cell generation [PMID:12577056]."},"prefetch_data":{"uniprot":{"accession":"Q9Y6W8","full_name":"Inducible T-cell costimulator","aliases":["Activation-inducible lymphocyte immunomediatory molecule"],"length_aa":199,"mass_kda":22.6,"function":"Stimulatory receptor expressed in activated or antigen-experienced T-cells that plays an important role in the immune response (PubMed:9930702). Upon binding to its ligand ICOSL expressed on antigen presenting cells (APCs), delivers costimulatory signals that enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines including IL10, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells (PubMed:33033255). Also acts as a costimulatory receptor critical for the differentiation of T follicular regulatory cells upon immune challenges such as viral infection (PubMed:27135603). Mechanistically, potentiates TCR-induced calcium flux by augmenting PLCG1 activation and actin remodeling (By similarity). In addition, activates PI3K signaling pathways independently of calcium flux (PubMed:30523347). Essential both for efficient interaction between T and B-cells and for normal antibody responses to T-cell dependent antigens. Prevents the apoptosis of pre-activated T-cells. Plays a critical role in CD40-mediated class switching of immunoglobin isotypes (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9Y6W8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ICOS","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ICOS","total_profiled":1310},"omim":[{"mim_id":"621096","title":"IMMUNODEFICIENCY 132B; IMD132B","url":"https://www.omim.org/entry/621096"},{"mim_id":"620825","title":"IMMUNODEFICIENCY 119; IMD119","url":"https://www.omim.org/entry/620825"},{"mim_id":"618998","title":"IMMUNE DYSREGULATION AND SYSTEMIC HYPERINFLAMMATION SYNDROME; IMDYSHI","url":"https://www.omim.org/entry/618998"},{"mim_id":"615606","title":"BUTYROPHILIN-LIKE PROTEIN 8; BTNL8","url":"https://www.omim.org/entry/615606"},{"mim_id":"615231","title":"RING FINGER AND CCCH-TYPE ZINC FINGER DOMAINS-CONTAINING PROTEIN 2; RC3H2","url":"https://www.omim.org/entry/615231"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Actin filaments","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":15.6},{"tissue":"lymphoid tissue","ntpm":18.8}],"url":"https://www.proteinatlas.org/search/ICOS"},"hgnc":{"alias_symbol":["AILIM","CD278"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y6W8","domains":[{"cath_id":"2.60.40.10","chopping":"28-132","consensus_level":"high","plddt":85.6648,"start":28,"end":132},{"cath_id":"1.20.5","chopping":"133-169","consensus_level":"medium","plddt":75.4978,"start":133,"end":169}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y6W8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y6W8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y6W8-F1-predicted_aligned_error_v6.png","plddt_mean":74.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ICOS","jax_strain_url":"https://www.jax.org/strain/search?query=ICOS"},"sequence":{"accession":"Q9Y6W8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y6W8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y6W8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y6W8"}},"corpus_meta":[{"pmid":"9930702","id":"PMC_9930702","title":"ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9930702","citation_count":1156,"is_preprint":false},{"pmid":"10617205","id":"PMC_10617205","title":"T-cell co-stimulation through B7RP-1 and ICOS.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10617205","citation_count":614,"is_preprint":false},{"pmid":"12577056","id":"PMC_12577056","title":"Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency.","date":"2003","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12577056","citation_count":541,"is_preprint":false},{"pmid":"11343123","id":"PMC_11343123","title":"ICOS is essential for effective T-helper-cell responses.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11343123","citation_count":514,"is_preprint":false},{"pmid":"29321369","id":"PMC_29321369","title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29321369","citation_count":462,"is_preprint":false},{"pmid":"23619696","id":"PMC_23619696","title":"Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23619696","citation_count":325,"is_preprint":false},{"pmid":"11046032","id":"PMC_11046032","title":"Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11046032","citation_count":323,"is_preprint":false},{"pmid":"12876557","id":"PMC_12876557","title":"Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.","date":"2003","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12876557","citation_count":285,"is_preprint":false},{"pmid":"25646266","id":"PMC_25646266","title":"ICOS maintains the T follicular helper cell phenotype by down-regulating Krüppel-like factor 2.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25646266","citation_count":246,"is_preprint":false},{"pmid":"24687957","id":"PMC_24687957","title":"Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.","date":"2014","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24687957","citation_count":240,"is_preprint":false},{"pmid":"27559335","id":"PMC_27559335","title":"ICOS Co-Stimulation: Friend or Foe?","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27559335","citation_count":234,"is_preprint":false},{"pmid":"25692700","id":"PMC_25692700","title":"ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation.","date":"2015","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25692700","citation_count":202,"is_preprint":false},{"pmid":"24292706","id":"PMC_24292706","title":"IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24292706","citation_count":201,"is_preprint":false},{"pmid":"12538658","id":"PMC_12538658","title":"Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12538658","citation_count":195,"is_preprint":false},{"pmid":"20116985","id":"PMC_20116985","title":"Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS).","date":"2010","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20116985","citation_count":175,"is_preprint":false},{"pmid":"26320067","id":"PMC_26320067","title":"Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.","date":"2015","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26320067","citation_count":168,"is_preprint":false},{"pmid":"20624644","id":"PMC_20624644","title":"Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.","date":"2010","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20624644","citation_count":143,"is_preprint":false},{"pmid":"11169414","id":"PMC_11169414","title":"Induction, binding specificity and function of human ICOS.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11169414","citation_count":138,"is_preprint":false},{"pmid":"32963045","id":"PMC_32963045","title":"Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma.","date":"2020","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32963045","citation_count":134,"is_preprint":false},{"pmid":"32516116","id":"PMC_32516116","title":"The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.","date":"2020","source":"ESMO open","url":"https://pubmed.ncbi.nlm.nih.gov/32516116","citation_count":130,"is_preprint":false},{"pmid":"12865411","id":"PMC_12865411","title":"The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12865411","citation_count":116,"is_preprint":false},{"pmid":"25918344","id":"PMC_25918344","title":"ICOS and Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties during tuberculosis.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25918344","citation_count":103,"is_preprint":false},{"pmid":"23319295","id":"PMC_23319295","title":"ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection.","date":"2013","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23319295","citation_count":96,"is_preprint":false},{"pmid":"32156777","id":"PMC_32156777","title":"ICOS Is an Indicator of T-cell-Mediated Response to Cancer Immunotherapy.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32156777","citation_count":95,"is_preprint":false},{"pmid":"31738626","id":"PMC_31738626","title":"Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.","date":"2019","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31738626","citation_count":94,"is_preprint":false},{"pmid":"11290772","id":"PMC_11290772","title":"ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11290772","citation_count":87,"is_preprint":false},{"pmid":"34932944","id":"PMC_34932944","title":"Engagement of the costimulatory molecule ICOS in tissues promotes establishment of CD8+ tissue-resident memory T cells.","date":"2021","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/34932944","citation_count":85,"is_preprint":false},{"pmid":"27895177","id":"PMC_27895177","title":"OX40 Cooperates with ICOS To Amplify Follicular Th Cell Development and Germinal Center Reactions during Infection.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27895177","citation_count":84,"is_preprint":false},{"pmid":"22815292","id":"PMC_22815292","title":"ICOS mediates the generation and function of CD4+CD25+Foxp3+ regulatory T cells conveying respiratory tolerance.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22815292","citation_count":82,"is_preprint":false},{"pmid":"14599850","id":"PMC_14599850","title":"Regulation of immune and autoimmune responses by ICOS.","date":"2003","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/14599850","citation_count":75,"is_preprint":false},{"pmid":"27467961","id":"PMC_27467961","title":"The clinical impact of ICOS signal in colorectal cancer patients.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27467961","citation_count":74,"is_preprint":false},{"pmid":"18390727","id":"PMC_18390727","title":"ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18390727","citation_count":72,"is_preprint":false},{"pmid":"29468927","id":"PMC_29468927","title":"Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.","date":"2018","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/29468927","citation_count":68,"is_preprint":false},{"pmid":"19426217","id":"PMC_19426217","title":"The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19426217","citation_count":68,"is_preprint":false},{"pmid":"35439168","id":"PMC_35439168","title":"PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35439168","citation_count":67,"is_preprint":false},{"pmid":"33087332","id":"PMC_33087332","title":"Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33087332","citation_count":67,"is_preprint":false},{"pmid":"11513541","id":"PMC_11513541","title":"ICOS ligand costimulation is required for T-cell encephalitogenicity.","date":"2001","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/11513541","citation_count":58,"is_preprint":false},{"pmid":"16580736","id":"PMC_16580736","title":"CD28 and ICOS: similar or separate costimulators of T cells?","date":"2006","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/16580736","citation_count":57,"is_preprint":false},{"pmid":"27812214","id":"PMC_27812214","title":"IFNAR1-Signalling Obstructs ICOS-mediated Humoral Immunity during Non-lethal Blood-Stage Plasmodium Infection.","date":"2016","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/27812214","citation_count":53,"is_preprint":false},{"pmid":"26667167","id":"PMC_26667167","title":"The Costimulatory Molecule ICOS Regulates Host Th1 and Follicular Th Cell Differentiation in Response to Plasmodium chabaudi chabaudi AS Infection.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26667167","citation_count":50,"is_preprint":false},{"pmid":"17889619","id":"PMC_17889619","title":"Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice.","date":"2007","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/17889619","citation_count":47,"is_preprint":false},{"pmid":"16221208","id":"PMC_16221208","title":"Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1.","date":"2005","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16221208","citation_count":46,"is_preprint":false},{"pmid":"37086778","id":"PMC_37086778","title":"Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression.","date":"2023","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/37086778","citation_count":45,"is_preprint":false},{"pmid":"34095875","id":"PMC_34095875","title":"Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways.","date":"2021","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34095875","citation_count":45,"is_preprint":false},{"pmid":"14999428","id":"PMC_14999428","title":"The role of ICOS and other costimulatory molecules in allergy and asthma.","date":"2004","source":"Springer seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/14999428","citation_count":44,"is_preprint":false},{"pmid":"12784384","id":"PMC_12784384","title":"Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis.","date":"2003","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/12784384","citation_count":44,"is_preprint":false},{"pmid":"33795388","id":"PMC_33795388","title":"Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33795388","citation_count":42,"is_preprint":false},{"pmid":"33033255","id":"PMC_33033255","title":"Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33033255","citation_count":41,"is_preprint":false},{"pmid":"16880206","id":"PMC_16880206","title":"Regulation of mouse inducible costimulator (ICOS) expression by Fyn-NFATc2 and ERK signaling in T cells.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16880206","citation_count":41,"is_preprint":false},{"pmid":"10607749","id":"PMC_10607749","title":"AILIM/ICOS: a novel lymphocyte adhesion molecule.","date":"2000","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10607749","citation_count":38,"is_preprint":false},{"pmid":"17013990","id":"PMC_17013990","title":"ICOS cooperates with CD28, IL-2, and IFN-gamma and modulates activation of human naïve CD4+ T cells.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17013990","citation_count":38,"is_preprint":false},{"pmid":"27798154","id":"PMC_27798154","title":"ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27798154","citation_count":37,"is_preprint":false},{"pmid":"11093165","id":"PMC_11093165","title":"The T cell activation molecule H4 and the CD28-like molecule ICOS are identical.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11093165","citation_count":37,"is_preprint":false},{"pmid":"16364152","id":"PMC_16364152","title":"CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma.","date":"2006","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/16364152","citation_count":36,"is_preprint":false},{"pmid":"26049110","id":"PMC_26049110","title":"ICOS promotes group 2 innate lymphoid cell activation in lungs.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26049110","citation_count":36,"is_preprint":false},{"pmid":"19299705","id":"PMC_19299705","title":"ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19299705","citation_count":36,"is_preprint":false},{"pmid":"15629449","id":"PMC_15629449","title":"ICOS costimulates invariant NKT cell activation.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15629449","citation_count":35,"is_preprint":false},{"pmid":"32999002","id":"PMC_32999002","title":"An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression.","date":"2020","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32999002","citation_count":35,"is_preprint":false},{"pmid":"31466995","id":"PMC_31466995","title":"Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.","date":"2019","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/31466995","citation_count":35,"is_preprint":false},{"pmid":"21925472","id":"PMC_21925472","title":"Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21925472","citation_count":35,"is_preprint":false},{"pmid":"15870016","id":"PMC_15870016","title":"Regulation of immune and autoimmune responses by ICOS-B7h interaction.","date":"2005","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/15870016","citation_count":34,"is_preprint":false},{"pmid":"25703015","id":"PMC_25703015","title":"A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation.","date":"2015","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/25703015","citation_count":34,"is_preprint":false},{"pmid":"29352114","id":"PMC_29352114","title":"Binding of NUFIP2 to Roquin promotes recognition and regulation of ICOS mRNA.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29352114","citation_count":33,"is_preprint":false},{"pmid":"14612664","id":"PMC_14612664","title":"The immunological synapse for B-cell memory: the role of the ICOS and its ligand for the longevity of humoral immunity.","date":"2003","source":"Current opinion in allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14612664","citation_count":32,"is_preprint":false},{"pmid":"30523347","id":"PMC_30523347","title":"Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling.","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30523347","citation_count":31,"is_preprint":false},{"pmid":"12594849","id":"PMC_12594849","title":"Mechanisms of H4/ICOS costimulation: effects on proximal TCR signals and MAP kinase pathways.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12594849","citation_count":31,"is_preprint":false},{"pmid":"38517331","id":"PMC_38517331","title":"ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38517331","citation_count":30,"is_preprint":false},{"pmid":"31962094","id":"PMC_31962094","title":"Immunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticles.","date":"2020","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/31962094","citation_count":29,"is_preprint":false},{"pmid":"33815374","id":"PMC_33815374","title":"Bacteroides thetaiotaomicron Ameliorates Experimental Allergic Airway Inflammation via Activation of ICOS+Tregs and Inhibition of Th2 Response.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33815374","citation_count":28,"is_preprint":false},{"pmid":"33707688","id":"PMC_33707688","title":"The ubiquitin ligase Peli1 inhibits ICOS and thereby Tfh-mediated immunity.","date":"2021","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33707688","citation_count":28,"is_preprint":false},{"pmid":"35508704","id":"PMC_35508704","title":"Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/35508704","citation_count":28,"is_preprint":false},{"pmid":"32212417","id":"PMC_32212417","title":"Exosome miR-27a-3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma.","date":"2020","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32212417","citation_count":28,"is_preprint":false},{"pmid":"31552030","id":"PMC_31552030","title":"CXCR5+PD1+ICOS+ Circulating T Follicular Helpers Are Associated With de novo Donor-Specific Antibodies After Renal Transplantation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31552030","citation_count":28,"is_preprint":false},{"pmid":"33095875","id":"PMC_33095875","title":"ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/33095875","citation_count":27,"is_preprint":false},{"pmid":"36774519","id":"PMC_36774519","title":"Inducible co-stimulatory molecule (ICOS) alleviates paclitaxel-induced neuropathic pain via an IL-10-mediated mechanism in female mice.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36774519","citation_count":27,"is_preprint":false},{"pmid":"29581356","id":"PMC_29581356","title":"ICOS Signaling Controls Induction and Maintenance of Collagen-Induced Arthritis.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29581356","citation_count":26,"is_preprint":false},{"pmid":"11839247","id":"PMC_11839247","title":"AILIM/ICOS: its expression and functional analysis with monoclonal antibodies.","date":"2001","source":"Hybridoma and hybridomics","url":"https://pubmed.ncbi.nlm.nih.gov/11839247","citation_count":26,"is_preprint":false},{"pmid":"18250437","id":"PMC_18250437","title":"ICOS, CD40, and lymphotoxin beta receptors signal sequentially and interdependently to initiate a germinal center reaction.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18250437","citation_count":26,"is_preprint":false},{"pmid":"33344450","id":"PMC_33344450","title":"Transcriptome Sequencing Reveals Potential Roles of ICOS in Primary Sjögren's Syndrome.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33344450","citation_count":26,"is_preprint":false},{"pmid":"15339883","id":"PMC_15339883","title":"AILIM/ICOS signaling induces T-cell migration/polarization of memory/effector T-cells.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15339883","citation_count":25,"is_preprint":false},{"pmid":"33881452","id":"PMC_33881452","title":"ICOS signaling limits regulatory T cell accumulation and function in visceral adipose tissue.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33881452","citation_count":25,"is_preprint":false},{"pmid":"16790364","id":"PMC_16790364","title":"Regulation of T:B cell interactions by the inducible costimulator molecule: does ICOS \"induce\" disease?","date":"2006","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/16790364","citation_count":25,"is_preprint":false},{"pmid":"30747722","id":"PMC_30747722","title":"Nonimmune cell-derived ICOS ligand functions as a renoprotective αvβ3 integrin-selective antagonist.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30747722","citation_count":25,"is_preprint":false},{"pmid":"27296665","id":"PMC_27296665","title":"Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27296665","citation_count":24,"is_preprint":false},{"pmid":"31858365","id":"PMC_31858365","title":"Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31858365","citation_count":23,"is_preprint":false},{"pmid":"17039567","id":"PMC_17039567","title":"A critical role for ICOS co-stimulation in immune containment of pulmonary influenza virus infection.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17039567","citation_count":22,"is_preprint":false},{"pmid":"34986869","id":"PMC_34986869","title":"Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.","date":"2022","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34986869","citation_count":21,"is_preprint":false},{"pmid":"27693916","id":"PMC_27693916","title":"Inducible costimulator (ICOS) potentiates TCR-induced calcium flux by augmenting PLCγ1 activation and actin remodeling.","date":"2016","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27693916","citation_count":21,"is_preprint":false},{"pmid":"17039566","id":"PMC_17039566","title":"The role of the ICOS/B7RP-1 T cell costimulatory pathway in murine experimental autoimmune uveoretinitis.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17039566","citation_count":21,"is_preprint":false},{"pmid":"22426168","id":"PMC_22426168","title":"CD4⁺Foxp3⁺ Treg and its ICOS⁺ subsets in patients with myocardial infarction.","date":"2012","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/22426168","citation_count":20,"is_preprint":false},{"pmid":"31283790","id":"PMC_31283790","title":"ICOS deficiency hampers the homeostasis, development and function of NK cells.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31283790","citation_count":20,"is_preprint":false},{"pmid":"17323353","id":"PMC_17323353","title":"ICOS and B7 costimulatory molecule expression identifies activated cellular subsets in rheumatoid arthritis.","date":"2007","source":"Cytometry. Part A : the journal of the International Society for Analytical Cytology","url":"https://pubmed.ncbi.nlm.nih.gov/17323353","citation_count":20,"is_preprint":false},{"pmid":"29377743","id":"PMC_29377743","title":"Leptin Upregulates Peripheral CD4+CXCR5+ICOS+ T Cells via Increased IL-6 in Rheumatoid Arthritis Patients.","date":"2018","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/29377743","citation_count":20,"is_preprint":false},{"pmid":"23024058","id":"PMC_23024058","title":"Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.","date":"2012","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23024058","citation_count":19,"is_preprint":false},{"pmid":"17481737","id":"PMC_17481737","title":"ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution.","date":"2007","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/17481737","citation_count":18,"is_preprint":false},{"pmid":"39269728","id":"PMC_39269728","title":"Discovery of ICOS-Targeted Small Molecules Using Affinity Selection Mass Spectrometry Screening.","date":"2024","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/39269728","citation_count":18,"is_preprint":false},{"pmid":"22577174","id":"PMC_22577174","title":"ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22577174","citation_count":18,"is_preprint":false},{"pmid":"16996590","id":"PMC_16996590","title":"Genetic variation in ICOS regulates mRNA levels of ICOS and splicing isoforms of CTLA4.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16996590","citation_count":18,"is_preprint":false},{"pmid":"30448635","id":"PMC_30448635","title":"PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction.","date":"2018","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30448635","citation_count":18,"is_preprint":false},{"pmid":"25754933","id":"PMC_25754933","title":"ICOS is required for the generation of both central and effector CD4(+) memory T-cell populations following acute bacterial infection.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25754933","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48491,"output_tokens":8525,"usd":0.136674},"stage2":{"model":"claude-opus-4-6","input_tokens":12410,"output_tokens":10709,"usd":0.494663},"total_usd":0.631337,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"ICOS is a homodimeric T-cell-specific cell-surface protein (Mr 55K-60K) that is de novo induced on T-cell surfaces upon activation (unlike constitutively expressed CD28), co-stimulates T-cell proliferation, lymphokine secretion, and B-cell help, superinduces IL-10 but does not upregulate IL-2, and is highly expressed on tonsillar germinal-centre T cells.\",\n      \"method\": \"Molecular cloning, flow cytometry, functional co-stimulation assays, immunohistochemistry\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original discovery paper with multiple orthogonal methods, highly cited, replicated across labs\",\n      \"pmids\": [\"9930702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ICOS (murine homologue) binds specifically to B7-related protein-1 (B7RP-1/ICOSL), a B7-family ligand expressed on B cells and macrophages; this receptor-ligand pair does not cross-interact with CD28, B7-1, or B7-2, defining a distinct co-stimulatory pathway.\",\n      \"method\": \"Receptor-ligand binding assays, fusion-protein co-stimulation, transgenic mouse overexpression\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding and functional co-stimulation assays, replicated by multiple labs\",\n      \"pmids\": [\"10617205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ICOS is essential in vivo for T-cell-dependent B-cell responses: ICOS-deficient mice show severely impaired germinal centre formation, defective immunoglobulin class switching (including IgE), reduced IL-4 production by primed T cells, and deficient T-B cell interactions.\",\n      \"method\": \"Gene-targeted ICOS-knockout mouse generation and phenotypic characterization, in vitro restimulation assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotypes, replicated by independent groups\",\n      \"pmids\": [\"11343123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ICOS expression is upregulated by CD28 co-stimulation (CD80/CD86-dependent) and promotes CD4+ T-cell proliferation and production of IFN-γ, IL-4, and IL-10 but not IL-2; blocking ICOS:B7h interaction shifts differentiation away from Th2 toward Th1.\",\n      \"method\": \"Anti-mouse ICOS mAbs and ICOS-Ig fusion protein blockade, bead-based co-stimulation assays, TCR-transgenic T-cell differentiation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays, replicated findings\",\n      \"pmids\": [\"11046032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Homozygous deletion of the ICOS gene in humans causes adult-onset common variable immunodeficiency with reduced naive, switched, and memory B cells, demonstrating ICOS is critical for T-cell help for late B-cell differentiation, class-switching, and memory B-cell generation.\",\n      \"method\": \"Genetic analysis (homozygous deletion), immunophenotyping of patient T and B cells\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human loss-of-function with defined immunological phenotype, highly cited\",\n      \"pmids\": [\"12577056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ICOS signals through PI3K (recruitment to ICOS cytoplasmic domain upon cross-linking) and enhances TCR-proximal signals including ZAP-70, zeta, Vav phosphorylation and ERK, JNK, and p38 MAP kinase activation; PI3K activity is required for ERK/JNK activation and IL-4/IL-10 secretion.\",\n      \"method\": \"ICOS cross-linking, kinase activity assays, PI3K inhibitors, phosphorylation western blots in Th2 clones\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical assays with inhibitors and mutagenesis, consistent with multiple studies\",\n      \"pmids\": [\"12594849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Human ICOS is a 55-60 kDa homodimer with N-glycosylated subunits of 27 and 29 kDa; it requires PMA plus ionomycin for full induction, is sensitive to cyclosporin A, does not bind B7-1 or B7-2, and maps to chromosome 2q33-34. CD28/B7 but not CD40L/CD40 pathway is critically involved in ICOS induction by APCs. ICOS co-stimulation prevents apoptosis of pre-activated T cells and superinduces IL-10.\",\n      \"method\": \"Biochemical characterization, flow cytometry, cytokine assays, chromosomal mapping\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical and functional methods in a single study\",\n      \"pmids\": [\"11169414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CTLA-4 ligation blocks ICOS co-stimulation both indirectly (by preventing ICOS surface expression on resting cells) and directly (by blocking ICOS-mediated IL-4, IL-10, IL-13 induction on pre-activated cells); exogenous IL-2 overcomes both mechanisms and is required for sustained ICOS-costimulated T-cell growth.\",\n      \"method\": \"Anti-CD3/anti-ICOS/anti-CTLA-4 bead stimulation, cytokine ELISA, IL-2 neutralization and addition experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with defined mechanistic dissection\",\n      \"pmids\": [\"11290772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ICOS expression is transcriptionally controlled by the Fyn-calcineurin-NFATc2 axis and a separate MEK2-ERK1/2 pathway; NFATc2 binds the icos promoter in vivo and this binding is reduced in Fyn-/- T cells; ectopic NFATc2 or constitutively active MEK2 transactivates a 288-bp core icos promoter region.\",\n      \"method\": \"Chemical inhibitors (PP2, U0126, CsA, FK506), luciferase reporter assays, ChIP, Fyn-/- mice\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter reporter, ChIP, and genetic KO with multiple inhibitors\",\n      \"pmids\": [\"16880206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ICOS directly drives follicular recruitment of activated T-helper cells by promoting pseudopod formation and persistent T-cell migration at the T-zone/B-follicle border; this requires ICOSL expression by follicular bystander B cells and is independent of ICOSL on dendritic cells or cognate B cells, and does not require Bcl6 as an intermediate.\",\n      \"method\": \"Two-photon intravital microscopy (dynamic imaging), ICOS-deficient and ICOSL conditional-KO mice, Bcl6 genetic analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct live imaging + genetic epistasis in vivo with multiple KO models\",\n      \"pmids\": [\"23619696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ICOS co-stimulation signals via PI3K to inactivate the transcription factor FOXO1, promoting Tfh cell differentiation; Foxo1 deletion rescues Tfh generation in ICOS-deficient conditions, while enforced nuclear FOXO1 blocks Tfh development even with ICOS overexpression; final GC-Tfh differentiation requires FOXO1 activity.\",\n      \"method\": \"Foxo1 conditional KO and nuclear-localization knock-in mice, ICOS-deficient mice, flow cytometry, gene expression analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple KO/KI models, mechanistic pathway defined\",\n      \"pmids\": [\"25692700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ICOS (but not CD28) co-stimulation is exclusively required for maintaining the Tfh phenotype by downregulating the transcription factor Klf2 via Foxo1; Klf2 directly binds to Cxcr5, Ccr7, Psgl-1, and S1pr1 promoters, and low Klf2 levels maintain the Tfh homing receptor pattern and follicular localization.\",\n      \"method\": \"ICOS blockade in vivo, Klf2 ChIP, conditional KO mice, gene expression and flow cytometry\",\n      \"journal\": \"Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP, genetic epistasis, ICOS blockade with defined transcriptional mechanism\",\n      \"pmids\": [\"25646266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The ICOS transmembrane domain (TMD) is required for association with the tyrosine kinase Lck, and this TMD-Lck association is necessary for p85 (PI3K regulatory subunit) recruitment to ICOS and downstream PI3K activation, as well as for costimulation of calcium mobilization; the ICOS cytoplasmic domain alone is insufficient for these functions. TMD-replaced ICOS fails to support Tfh development or GC formation in vivo.\",\n      \"method\": \"ICOS domain-swap constructs, co-immunoprecipitation, calcium flux assays, Lck co-association, in vivo Tfh/GC analysis\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — domain mutagenesis with reconstitution, biochemical co-IP, and in vivo validation\",\n      \"pmids\": [\"30523347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ICOS potentiates TCR-induced calcium flux by enhancing PLCγ1 activation and actin remodeling (via RhoA and Cdc42 activation); a membrane-proximal cytoplasmic motif is essential for this calcium-signaling function; interruption of actin dynamics impairs calcium flux even with activated PLCγ1.\",\n      \"method\": \"ICOS cytoplasmic domain mutagenesis knock-in mice, calcium flux assays, PLCγ1 phosphorylation assays, small GTPase activation assays, actin inhibitors\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — domain mutagenesis KI mice, biochemical assays with multiple inhibitors\",\n      \"pmids\": [\"27693916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Peli1 (an E3 ubiquitin ligase) negatively regulates ICOS expression by limiting c-Rel-mediated ICOS transcription; increased ICOS in Peli1-KO T cells enhances PI3K-AKT signaling, suppresses Klf2, and promotes Tfh differentiation.\",\n      \"method\": \"Mixed bone marrow chimeras, Peli1-KO mice, c-Rel analysis, PI3K-AKT signaling assays, Klf2 reconstitution\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO, rescue experiments, defined signaling pathway\",\n      \"pmids\": [\"33707688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structure of the ICOS/ICOS-L complex at 3.3 Å resolution reveals that a central FDPPPF motif and CC' loop residues of ICOS mediate specificity of ICOS-L binding with a distinct receptor orientation compared to CD28/B7; the N110 N-linked glycan of ICOS participates directly in ICOS-L binding.\",\n      \"method\": \"X-ray crystallography (3.3 Å), binding assays, structural comparison\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional binding validation\",\n      \"pmids\": [\"33033255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Binding of NUFIP2 to Roquin-1/2 promotes recognition of ICOS mRNA; post-transcriptional repression of human ICOS by Roquin requires two neighboring non-canonical stem-loops in the ICOS 3'-UTR; NUFIP2 binds Roquin directly with high affinity, stabilizing NUFIP2, and acts as a cofactor for cooperative mRNA target recognition.\",\n      \"method\": \"RNAi screen (~1500 genes), co-immunoprecipitation, RNA-binding assays, ICOS 3'-UTR stem-loop mutagenesis, NUFIP2-Roquin binding assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide screen, direct binding assays, UTR mutagenesis\",\n      \"pmids\": [\"29352114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In the germinal centre reaction, ICOS signaling acts upstream of CD40 and lymphotoxin beta receptor (LTβR): ICOS activation on T cells induces LTαβ on B cells in vitro; GC B cells from ICOS-/- mice show reduced LTαβ expression; agonistic anti-CD40 restores GC networks and LTαβ on GC B cells in ICOS-/- mice in a LTβR-dependent manner.\",\n      \"method\": \"ICOS-/- mice, in vitro T-B co-stimulation, agonistic antibody treatment, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + in vitro and in vivo rescue experiments defining pathway order\",\n      \"pmids\": [\"18250437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ICOS engagement in tissues (via ICOSL expressed in tissue) promotes establishment but not maintenance of CD8+ tissue-resident memory (Trm) T cells; this function requires ICOS-mediated PI3K signaling (IcosYF/YF knock-in mice show defective Trm generation); ICOS ligation during priming does not determine Trm induction—local tissue ICOS signaling during effector phase is the critical step.\",\n      \"method\": \"ICOS-/- and IcosYF/YF knock-in mice, Icosl-/- host transfers, ICOS-L blockade, adoptive transfer experiments, flow cytometry\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO/KI genetic models with defined PI3K signaling requirement and temporal dissection\",\n      \"pmids\": [\"34932944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The ICOS intracellular domain (ICD) enhances in vivo persistence of CAR-expressing CD4+ T cells, and a CAR combining ICOS and 4-1BB ICDs shows superior antitumor effects; the membrane-proximal ICD exerts dominant signaling, and optimal function requires the ICOS ICD linked to the ICOS transmembrane domain.\",\n      \"method\": \"CAR T-cell mouse tumor models, in vivo persistence assays, domain-swap constructs\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain-swap constructs with in vivo functional readouts\",\n      \"pmids\": [\"29321369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ICOS signaling (via the Tyr181-based PI3K-binding SH2 motif) is required for induction of collagen-induced arthritis including antibody production and expansion of inflammatory T cells, and for maintenance of CIA in an antibody-independent manner; glycolysis inhibition (3-bromopyruvate) ameliorates established CIA, linking ICOS-PI3K signaling to glucose metabolism.\",\n      \"method\": \"ICOS KO and PI3K-binding motif knock-in mice, collagen-induced arthritis model, glycolysis inhibitor treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO and KI genetic dissection with defined signaling motif and metabolic link\",\n      \"pmids\": [\"29581356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"AILIM (rat ICOS ortholog) functions as a lymphocyte adhesion molecule; AILIM-transfected cells aggregate in an AILIM-dependent manner and human thymoma cells bind purified AILIM, suggesting an adhesion function for ICOS beyond co-stimulation.\",\n      \"method\": \"Cell aggregation assays, AILIM gene transfection, binding assays with purified protein\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding and cell aggregation assays, but single lab with rat ortholog\",\n      \"pmids\": [\"10607749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ICOS/AILIM signaling induces transendothelial migration and morphological polarization of memory/effector CD4+ T cells (but not naïve or Th2 cells) via interaction with B7h on TNF-α-treated endothelial cells, and is involved in Th1 cell trafficking into peripheral tissues.\",\n      \"method\": \"Transwell migration assays, T-cell polarization imaging, anti-ICOS/AILIM stimulation, human endothelial cell co-culture\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct functional assays but single lab\",\n      \"pmids\": [\"15339883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ICOS signaling is required for generation and suppressive function of CD4+CD25+Foxp3+ regulatory T cells that convey respiratory tolerance; ICOS-/- Tregs produce significantly less IL-10 and fail to suppress airway inflammation when transferred to asthmatic recipients.\",\n      \"method\": \"ICOS-/- mice, anti-ICOSL blocking antibody, adoptive Treg transfer experiments, cytokine assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent genetic/pharmacological approaches with defined functional readout\",\n      \"pmids\": [\"22815292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ICOS controls Foxp3+ Treg expansion and maintenance during helminth infection; ICOS deficiency increases Treg apoptosis, impairs Treg-specific IL-10 production, and prevents adaptive (Helios-) Treg responses in the intestinal lamina propria, with tissue-specific consequences on type 2 immunity.\",\n      \"method\": \"ICOS-/- mice infected with H. polygyrus or S. mansoni, flow cytometry, apoptosis assays, IL-10 intracellular staining\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mice with defined Treg-specific functional readouts across two helminth models\",\n      \"pmids\": [\"23319295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ICOS co-stimulates invariant NKT (iNKT) cell activation; iNKT cells constitutively express ICOS and upregulate it after α-GalCer treatment; blockade of ICOS-ICOSL or ICOS gene knockout substantially inhibits α-GalCer-induced IFN-γ, IL-4 production, cytotoxic activity, and anti-metastatic effects; CD28 and ICOS act independently.\",\n      \"method\": \"ICOS-/- mice, anti-B7RP-1 mAb blockade, α-GalCer challenge, cytokine assays, cytotoxicity assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO + pharmacological blockade with multiple functional readouts\",\n      \"pmids\": [\"15629449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ICOS/ICOSL interaction is required for CD4+ iNKT cell function and homeostatic survival; ICOS-/- and ICOSL-/- mice have significantly fewer CD4+ iNKT cells; ICOS-/- iNKT cells fail to produce IL-4 and IL-13 upon activation and cannot reconstitute airway hyperreactivity; ICOSL-/- environment induces apoptosis of transferred WT iNKT cells.\",\n      \"method\": \"ICOS-/- and ICOSL-/- mice, adoptive transfer, α-GalCer challenge, apoptosis assays, cytokine assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dual KO mouse models with adoptive transfer and multiple functional readouts\",\n      \"pmids\": [\"18390727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ICOS-ICOSL signaling promotes skin wound healing by sustaining inflammatory cell infiltration and cytokine production (especially Th2 cytokines IL-4, IL-6, IL-10) at the wound site; ICOS-/-, ICOSL-/-, and double-KO mice each show equivalent delays in wound healing with suppressed keratinocyte migration, angiogenesis, and granulation tissue; IL-6 (but not IL-4) application restores early healing in KO mice.\",\n      \"method\": \"ICOS-/-, ICOSL-/-, and double-KO mice, excisional wound model, T-cell transfer/depletion, cytokine rescue experiments\",\n      \"journal\": \"American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three genetic KO models + rescue with specific cytokine\",\n      \"pmids\": [\"21925472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ICOS promotes activation of ILC2s in lungs: B7RP-1 co-culture increases ILC2 cytokine production; blocking ICOS/B7RP-1 interaction abrogates ILC2 expansion and eosinophil influx induced by papain; lung DCs express B7RP-1 and may serve as the ICOSL-expressing partner for ILC2s.\",\n      \"method\": \"ILC2 purification, B7RP-1-transfected cell co-culture, blocking mAb, papain-challenge mouse model, flow cytometry\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vitro and in vivo blockade, single lab\",\n      \"pmids\": [\"26049110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ICOS controls effector function (cytokine production and local proliferation) but not trafficking receptor expression (CXCR3, P-selectin ligand) of kidney-infiltrating CD4+ T cells in murine lupus; ICOS-/- MRL(lpr) effector cells migrate normally to CXCL9 but fail to produce inflammatory cytokines and show impaired in-situ proliferation.\",\n      \"method\": \"Genetic ablation (ICOS-/- MRL/lpr mice), chemokine/receptor flow cytometry, migration assays, cytokine assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with mechanistic dissection of trafficking vs. effector function\",\n      \"pmids\": [\"19299705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ICOS signaling limits VAT-Treg accumulation and function in visceral adipose tissue via cell-intrinsic PI3K signaling; ICOS-/- mice and PI3K-binding knock-in mice show increased VAT-Treg abundance with elevated VAT-Treg markers, enhanced CCR3-dependent accumulation, reduced adipose inflammation, and improved insulin sensitivity on high-fat diet.\",\n      \"method\": \"ICOS-/- and IcosYF/YF knock-in mice, high-fat diet model, flow cytometry, CCR3 expression analysis\",\n      \"journal\": \"Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dual KO/KI genetic models identifying PI3K-dependent mechanism in metabolic context\",\n      \"pmids\": [\"33881452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ICOSL (ICOS ligand) on non-immune podocytes contains an RGD motif that allows high-affinity, selective binding to αvβ3 integrin, limiting its activation; ICOSL deficiency in mice increases susceptibility to proteinuria rescued by recombinant ICOSL, revealing a renoprotective, immune-independent function of ICOSL as an endogenous αvβ3-selective antagonist.\",\n      \"method\": \"RGD motif mutagenesis, integrin binding assays, Icosl-/- mice, proteinuria models, recombinant ICOSL rescue\",\n      \"journal\": \"Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — RGD mutagenesis, direct binding assays, KO mouse model with rescue\",\n      \"pmids\": [\"30747722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Intrathecal administration of an ICOS agonist antibody alleviates paclitaxel-induced neuropathic mechanical hypersensitivity in female mice via an IL-10-mediated mechanism in the dorsal root ganglion; blocking IL-10 receptor occludes the analgesic effect; ICOS agonism also reduces astrogliosis and satellite cell gliosis.\",\n      \"method\": \"Intrathecal ICOS agonist injection, IL-10R blocking antibody, spared nerve injury model, DRG IL-10 quantification, gliosis assessment\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined IL-10 mechanism with receptor blocking, single lab\",\n      \"pmids\": [\"36774519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Adipocyte-derived exosomal miR-27a-3p targets the ICOS 3'-UTR to suppress ICOS expression on T cells (confirmed by dual-luciferase reporter assay), reducing ICOS+ T-cell proliferation and IFN-γ secretion, providing a mechanism for obesity-associated enhancement of antitumor immunity.\",\n      \"method\": \"Dual-luciferase reporter assay (miR-27a-3p vs. ICOS 3'-UTR), exosome isolation, flow cytometry, IFN-γ ELISA\",\n      \"journal\": \"Thoracic cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct 3'-UTR reporter validation, single lab\",\n      \"pmids\": [\"32212417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"During inflammation, ICOSL upregulation on immunofibroblasts (and DCs) enables ICOS+ T-cell binding to induce LTα3 production, which drives chemokine production required for tertiary lymphoid structure (TLS) assembly via TNFRI/II engagement; pharmacological or genetic ICOS/ICOS-L blockade results in defective LTα expression and abrogates TLS formation.\",\n      \"method\": \"Genetic and pharmacological ICOS/ICOSL blockade, mouse and human tissue analysis, immunofibroblast-T cell co-culture\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic and pharmacological blocking with in vivo and in vitro validation, single primary lab\",\n      \"pmids\": [\"35508704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ICOS triggering of osteoclast-expressed ICOSL (B7h) by recombinant ICOS-Fc inhibits RANKL-mediated osteoclast differentiation (suppressing NFATc1, DC-STAMP, OSCAR, TRAP, cathepsin K) and reduces bone loss in ovariectomized mice in vivo.\",\n      \"method\": \"ICOS-Fc treatment of human monocyte-derived osteoclast-like cells, osteolytic activity assays, ovariectomy mouse model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro differentiation assays plus in vivo bone loss model, single lab\",\n      \"pmids\": [\"27798154\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ICOS is an activation-induced homodimeric T-cell co-stimulatory receptor that binds specifically to ICOSL (B7RP-1) via a central FDPPPF motif and CC' loop (with N-linked glycan participation), recruits Lck through its transmembrane domain to enable p85/PI3K activation, and signals via PI3K-AKT to inactivate FOXO1 (promoting Tfh differentiation), enhance PLCγ1-dependent calcium flux and actin remodeling (via RhoA/Cdc42), and activate ERK/JNK/p38 MAP kinases; its expression is transcriptionally regulated by Fyn-calcineurin-NFATc2 and MEK-ERK axes and post-transcriptionally repressed by Roquin/NUFIP2-mediated mRNA decay targeting stem-loops in the ICOS 3'-UTR; through these pathways ICOS drives germinal centre formation (upstream of CD40-LTβR), Tfh maintenance via Klf2 downregulation, Treg IL-10 production and suppressive function, CD8+ tissue-resident memory T-cell establishment, and iNKT cell activation, while CTLA-4 and Peli1 (E3 ubiquitin ligase) serve as negative regulators of ICOS signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ICOS is an activation-induced T-cell co-stimulatory receptor that, through its exclusive ligand ICOSL (B7RP-1), drives germinal centre formation, T follicular helper (Tfh) cell differentiation and maintenance, regulatory T-cell IL-10 production, iNKT cell activation, and CD8+ tissue-resident memory T-cell establishment [PMID:9930702, PMID:11343123, PMID:25692700, PMID:34932944, PMID:18390727, PMID:22815292]. Structurally, ICOS binds ICOSL via a central FDPPPF motif and CC' loop with direct participation of an N110-linked glycan, and its transmembrane domain recruits Lck, which is required for p85/PI3K recruitment to the ICOS cytoplasmic tail; downstream PI3K-AKT signaling inactivates FOXO1 to suppress Klf2, thereby establishing the Tfh homing receptor program, while a membrane-proximal cytoplasmic motif potentiates PLCγ1-dependent calcium flux and RhoA/Cdc42-mediated actin remodeling [PMID:33033255, PMID:30523347, PMID:12594849, PMID:25692700, PMID:25646266, PMID:27693916]. ICOS expression is transcriptionally controlled by Fyn–calcineurin–NFATc2 and MEK–ERK pathways, and post-transcriptionally repressed by Roquin/NUFIP2-mediated decay targeting stem-loops in the ICOS 3′-UTR [PMID:16880206, PMID:29352114]. Homozygous ICOS deletion in humans causes common variable immunodeficiency characterized by defective B-cell class-switching and memory B-cell generation [PMID:12577056].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of ICOS as a novel activation-induced T-cell co-stimulatory receptor established that the CD28 superfamily contained a second, non-redundant co-stimulatory pathway with distinct cytokine output (IL-10 superinduction, no IL-2 upregulation).\",\n      \"evidence\": \"Molecular cloning, flow cytometry, functional co-stimulation assays, and immunohistochemistry of human tonsil T cells\",\n      \"pmids\": [\"9930702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity unknown at time of discovery\", \"Signaling pathway downstream of ICOS uncharacterized\", \"Tissue distribution beyond tonsil not fully mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery of B7RP-1/ICOSL as the exclusive ICOS ligand, and demonstration that ICOS–ICOSL and CD28–B7 systems do not cross-react, defined two parallel but independent co-stimulatory axes in adaptive immunity.\",\n      \"evidence\": \"Receptor–ligand binding assays and fusion-protein co-stimulation in murine system; additional biochemical characterization of human ICOS homodimer\",\n      \"pmids\": [\"10617205\", \"11169414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ligand specificity unknown\", \"ICOS–ICOSL affinity and kinetics not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"ICOS knockout mice revealed that ICOS is essential in vivo for germinal centre formation, Ig class switching, and T-dependent B-cell responses, while CTLA-4 was shown to antagonize ICOS-mediated cytokine production, establishing a co-stimulatory/co-inhibitory regulatory circuit.\",\n      \"evidence\": \"ICOS-deficient mouse phenotyping; anti-CTLA-4/anti-ICOS bead stimulation and IL-2 rescue experiments\",\n      \"pmids\": [\"11343123\", \"11290772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling intermediates not identified\", \"Mechanism of CTLA-4 suppression of ICOS expression unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Human ICOS deficiency was linked to common variable immunodeficiency, and ICOS signaling was shown to proceed through PI3K recruitment and MAP kinase activation, connecting receptor engagement to cytokine gene regulation.\",\n      \"evidence\": \"Homozygous ICOS deletion in patients with immunophenotyping; ICOS cross-linking with PI3K inhibitors and kinase assays in Th2 clones\",\n      \"pmids\": [\"12577056\", \"12594849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PI3K-binding motif on ICOS not mapped\", \"Transcription factors downstream of PI3K not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defining the Fyn–calcineurin–NFATc2 and MEK–ERK transcriptional circuits controlling ICOS promoter activity explained how TCR signal strength and co-stimulation regulate ICOS expression levels.\",\n      \"evidence\": \"ChIP of NFATc2 on icos promoter, luciferase reporters, Fyn−/− T cells, chemical inhibitors\",\n      \"pmids\": [\"16880206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin accessibility and epigenetic regulation of icos locus not addressed\", \"Post-transcriptional regulation not yet characterized\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Epistasis experiments placed ICOS upstream of CD40 and LTβR in germinal centre network formation, and demonstrated ICOS is required for iNKT cell homeostasis and effector function, broadening ICOS function beyond conventional T cells.\",\n      \"evidence\": \"ICOS−/− mice with agonistic anti-CD40 rescue; ICOS−/− and ICOSL−/− mice with α-GalCer challenge and adoptive iNKT transfer\",\n      \"pmids\": [\"18250437\", \"18390727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking ICOS to LTαβ induction on B cells not defined\", \"iNKT-intrinsic vs. extrinsic ICOS requirement not fully separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two-photon imaging showed ICOS drives T-cell pseudopod formation and persistent migration at the T–B border via bystander B-cell ICOSL, explaining how ICOS positions T cells for follicular entry independently of Bcl6; separately, ICOS was shown essential for Treg IL-10 production and suppressive function.\",\n      \"evidence\": \"Intravital two-photon microscopy with ICOS-deficient and ICOSL conditional-KO mice; ICOS−/− Treg transfer in airway tolerance and helminth models\",\n      \"pmids\": [\"23619696\", \"22815292\", \"23319295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoskeletal effectors downstream of ICOS mediating pseudopod formation not identified\", \"Whether ICOS-dependent Treg IL-10 operates through PI3K–FOXO1 untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic epistasis established that ICOS signals through PI3K to inactivate FOXO1, which in turn represses Klf2; Klf2 directly controls Tfh homing receptors (CXCR5, CCR7, PSGL1, S1PR1), providing a complete transcriptional pathway from receptor to cell positioning.\",\n      \"evidence\": \"Foxo1 conditional KO and nuclear-localization KI mice crossed to ICOS−/−; Klf2 ChIP on Tfh target promoters with ICOS blockade\",\n      \"pmids\": [\"25692700\", \"25646266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional transcription factors act in parallel with FOXO1 downstream of ICOS not tested\", \"Kinetics of FOXO1 inactivation upon ICOS ligation not measured\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A membrane-proximal cytoplasmic motif of ICOS was shown to potentiate calcium signaling via PLCγ1 activation and RhoA/Cdc42-dependent actin remodeling, revealing a PI3K-independent arm of ICOS signaling.\",\n      \"evidence\": \"ICOS cytoplasmic domain mutagenesis knock-in mice with calcium flux, PLCγ1 phosphorylation, and small GTPase activation assays\",\n      \"pmids\": [\"27693916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the adaptor linking the proximal motif to RhoA/Cdc42 unknown\", \"Relative contribution of calcium vs. PI3K arm to individual T-cell fates not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The ICOS transmembrane domain was identified as the site of Lck association, which is prerequisite for p85/PI3K recruitment and downstream Tfh/GC responses, resolving how ICOS activates PI3K despite lacking a classical ITAM; simultaneously, Roquin/NUFIP2-dependent mRNA decay targeting dual stem-loops in the ICOS 3′-UTR was established as the major post-transcriptional brake on ICOS levels, and Peli1 was identified as a transcriptional negative regulator via c-Rel.\",\n      \"evidence\": \"Domain-swap constructs with co-IP and in vivo Tfh/GC analysis; genome-wide RNAi screen with 3′-UTR mutagenesis; Peli1-KO mice with PI3K-AKT and Klf2 readouts\",\n      \"pmids\": [\"30523347\", \"29352114\", \"33707688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of TMD–Lck interaction unresolved\", \"How Roquin selects ICOS mRNA over other targets not fully elucidated\", \"Whether Peli1 directly ubiquitinates c-Rel to limit ICOS transcription not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The crystal structure of the ICOS–ICOSL complex at 3.3 Å revealed that the FDPPPF motif and CC' loop (with N110 glycan) mediate ligand specificity via a binding orientation distinct from CD28–B7, providing a structural rationale for the non-cross-reactivity of these pathways.\",\n      \"evidence\": \"X-ray crystallography at 3.3 Å with binding-assay validation\",\n      \"pmids\": [\"33033255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of full-length ICOS including TMD and cytoplasmic domain\", \"Dynamics of ICOS dimerization and its role in signaling complex assembly not characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ICOS–PI3K signaling in the tissue effector phase was shown to be required for establishment of CD8+ tissue-resident memory T cells independently of priming, expanding the functional repertoire of ICOS beyond CD4+ T-cell help; in a distinct context, ICOS–PI3K signaling was found to limit visceral adipose tissue Treg accumulation, revealing context-dependent effects on Treg biology.\",\n      \"evidence\": \"ICOS−/− and IcosYF/YF KI mice with adoptive transfer and temporal ICOSL blockade for Trm; same genetic models on high-fat diet for VAT-Treg analysis\",\n      \"pmids\": [\"34932944\", \"33881452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of PI3K that distinguish Trm establishment from Tfh programming not identified\", \"Whether ICOS limits VAT-Tregs through FOXO1–Klf2 axis specifically not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of TMD–Lck association, how ICOS signal strength is integrated across the PI3K and calcium arms to specify distinct T-cell fates (Tfh vs. Treg vs. Trm), and whether ICOS-dependent metabolic reprogramming (glycolysis) is a general feature of its signaling or context-restricted.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of ICOS TMD–Lck interface\", \"Quantitative signaling model integrating PI3K and PLCγ1 arms absent\", \"Metabolic consequences of ICOS signaling tested only in CIA model\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5, 15]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [21, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [5, 10, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4, 23, 24, 25, 26]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 10, 11, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ICOSL\",\n      \"LCK\",\n      \"PIK3R1\",\n      \"FOXO1\",\n      \"NFATC2\",\n      \"RC3H1\",\n      \"NUFIP2\",\n      \"PELI1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway term_ids. Let me correct them — they should be Reactome IDs from the allowed list.\n\n```json\n{\n  \"mechanistic_narrative\": \"ICOS is an activation-induced T-cell co-stimulatory receptor that, through its exclusive ligand ICOSL (B7RP-1), drives germinal centre formation, T follicular helper (Tfh) cell differentiation and maintenance, regulatory T-cell IL-10 production, iNKT cell activation, and CD8+ tissue-resident memory T-cell establishment [PMID:9930702, PMID:11343123, PMID:25692700, PMID:34932944, PMID:18390727, PMID:22815292]. Structurally, ICOS binds ICOSL via a central FDPPPF motif and CC' loop with direct participation of an N110-linked glycan, and its transmembrane domain recruits Lck, which is required for p85/PI3K recruitment to the cytoplasmic tail; downstream PI3K–AKT signaling inactivates FOXO1 to suppress Klf2, establishing the Tfh homing receptor program, while a membrane-proximal cytoplasmic motif potentiates PLCγ1-dependent calcium flux and RhoA/Cdc42-mediated actin remodeling [PMID:33033255, PMID:30523347, PMID:12594849, PMID:25692700, PMID:25646266, PMID:27693916]. ICOS expression is transcriptionally controlled by Fyn–calcineurin–NFATc2 and MEK–ERK pathways and post-transcriptionally repressed by Roquin/NUFIP2-mediated mRNA decay targeting stem-loops in the ICOS 3′-UTR [PMID:16880206, PMID:29352114]. Homozygous ICOS deletion in humans causes common variable immunodeficiency characterized by defective B-cell class-switching and memory B-cell generation [PMID:12577056].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of ICOS as a novel activation-induced T-cell co-stimulatory receptor established that the CD28 superfamily contained a second, non-redundant co-stimulatory pathway with distinct cytokine output (IL-10 superinduction, no IL-2 upregulation).\",\n      \"evidence\": \"Molecular cloning, flow cytometry, functional co-stimulation assays, and immunohistochemistry of human tonsil T cells\",\n      \"pmids\": [\"9930702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity unknown at time of discovery\", \"Signaling pathway downstream of ICOS uncharacterized\", \"Tissue distribution beyond tonsil not fully mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery of B7RP-1/ICOSL as the exclusive ICOS ligand, and demonstration that ICOS–ICOSL and CD28–B7 systems do not cross-react, defined two parallel but independent co-stimulatory axes in adaptive immunity.\",\n      \"evidence\": \"Receptor–ligand binding assays and fusion-protein co-stimulation in murine system; additional biochemical characterization of human ICOS homodimer\",\n      \"pmids\": [\"10617205\", \"11169414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ligand specificity unknown\", \"ICOS–ICOSL affinity and kinetics not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"ICOS knockout mice revealed that ICOS is essential in vivo for germinal centre formation, Ig class switching, and T-dependent B-cell responses, while CTLA-4 was shown to antagonize ICOS-mediated cytokine production, establishing a co-stimulatory/co-inhibitory regulatory circuit.\",\n      \"evidence\": \"ICOS-deficient mouse phenotyping; anti-CTLA-4/anti-ICOS bead stimulation and IL-2 rescue experiments\",\n      \"pmids\": [\"11343123\", \"11290772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling intermediates not identified\", \"Mechanism of CTLA-4 suppression of ICOS expression unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Human ICOS deficiency was linked to common variable immunodeficiency, and ICOS signaling was shown to proceed through PI3K recruitment and MAP kinase activation, connecting receptor engagement to cytokine gene regulation.\",\n      \"evidence\": \"Homozygous ICOS deletion in patients with immunophenotyping; ICOS cross-linking with PI3K inhibitors and kinase assays in Th2 clones\",\n      \"pmids\": [\"12577056\", \"12594849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PI3K-binding motif on ICOS not mapped\", \"Transcription factors downstream of PI3K not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defining the Fyn–calcineurin–NFATc2 and MEK–ERK transcriptional circuits controlling ICOS promoter activity explained how TCR signal strength and co-stimulation regulate ICOS expression levels.\",\n      \"evidence\": \"ChIP of NFATc2 on icos promoter, luciferase reporters, Fyn−/− T cells, chemical inhibitors\",\n      \"pmids\": [\"16880206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin accessibility and epigenetic regulation of icos locus not addressed\", \"Post-transcriptional regulation not yet characterized\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Epistasis experiments placed ICOS upstream of CD40 and LTβR in germinal centre network formation, and demonstrated ICOS is required for iNKT cell homeostasis and effector function, broadening ICOS function beyond conventional T cells.\",\n      \"evidence\": \"ICOS−/− mice with agonistic anti-CD40 rescue; ICOS−/− and ICOSL−/− mice with α-GalCer challenge and adoptive iNKT transfer\",\n      \"pmids\": [\"18250437\", \"18390727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking ICOS to LTαβ induction on B cells not defined\", \"iNKT-intrinsic vs. extrinsic ICOS requirement not fully separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two-photon imaging showed ICOS drives T-cell pseudopod formation and persistent migration at the T–B border via bystander B-cell ICOSL, explaining how ICOS positions T cells for follicular entry independently of Bcl6; separately, ICOS was shown essential for Treg IL-10 production and suppressive function.\",\n      \"evidence\": \"Intravital two-photon microscopy with ICOS-deficient and ICOSL conditional-KO mice; ICOS−/− Treg transfer in airway tolerance and helminth models\",\n      \"pmids\": [\"23619696\", \"22815292\", \"23319295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoskeletal effectors downstream of ICOS mediating pseudopod formation not identified\", \"Whether ICOS-dependent Treg IL-10 operates through PI3K–FOXO1 untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic epistasis established that ICOS signals through PI3K to inactivate FOXO1, which in turn represses Klf2; Klf2 directly controls Tfh homing receptors (CXCR5, CCR7, PSGL1, S1PR1), providing a complete transcriptional pathway from receptor to cell positioning.\",\n      \"evidence\": \"Foxo1 conditional KO and nuclear-localization KI mice crossed to ICOS−/−; Klf2 ChIP on Tfh target promoters with ICOS blockade\",\n      \"pmids\": [\"25692700\", \"25646266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional transcription factors act in parallel with FOXO1 downstream of ICOS not tested\", \"Kinetics of FOXO1 inactivation upon ICOS ligation not measured\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A membrane-proximal cytoplasmic motif of ICOS was shown to potentiate calcium signaling via PLCγ1 activation and RhoA/Cdc42-dependent actin remodeling, revealing a PI3K-independent arm of ICOS signaling.\",\n      \"evidence\": \"ICOS cytoplasmic domain mutagenesis knock-in mice with calcium flux, PLCγ1 phosphorylation, and small GTPase activation assays\",\n      \"pmids\": [\"27693916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the adaptor linking the proximal motif to RhoA/Cdc42 unknown\", \"Relative contribution of calcium vs. PI3K arm to individual T-cell fates not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The ICOS transmembrane domain was identified as the site of Lck association prerequisite for p85/PI3K recruitment, resolving how ICOS activates PI3K; simultaneously, Roquin/NUFIP2-dependent mRNA decay targeting dual stem-loops in the ICOS 3′-UTR was established as the major post-transcriptional brake on ICOS levels, and Peli1 was identified as a transcriptional negative regulator via c-Rel.\",\n      \"evidence\": \"Domain-swap constructs with co-IP and in vivo Tfh/GC analysis; genome-wide RNAi screen with 3′-UTR mutagenesis; Peli1-KO mice with PI3K–AKT and Klf2 readouts\",\n      \"pmids\": [\"30523347\", \"29352114\", \"33707688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of TMD–Lck interaction unresolved\", \"How Roquin selects ICOS mRNA over other targets not fully elucidated\", \"Whether Peli1 directly ubiquitinates c-Rel to limit ICOS transcription not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The crystal structure of the ICOS–ICOSL complex at 3.3 Å revealed that the FDPPPF motif and CC' loop (with N110 glycan) mediate ligand specificity via a binding orientation distinct from CD28–B7, providing a structural rationale for the non-cross-reactivity of these pathways.\",\n      \"evidence\": \"X-ray crystallography at 3.3 Å with binding-assay validation\",\n      \"pmids\": [\"33033255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of full-length ICOS including TMD and cytoplasmic domain\", \"Dynamics of ICOS dimerization and its role in signaling complex assembly not characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ICOS–PI3K signaling in the tissue effector phase was shown to be required for establishment of CD8+ tissue-resident memory T cells independently of priming, expanding the functional repertoire of ICOS beyond CD4+ T-cell help; in a distinct context, ICOS–PI3K signaling was found to limit visceral adipose tissue Treg accumulation, revealing context-dependent effects on Treg biology.\",\n      \"evidence\": \"ICOS−/− and IcosYF/YF KI mice with adoptive transfer and temporal ICOSL blockade for Trm; same genetic models on high-fat diet for VAT-Treg analysis\",\n      \"pmids\": [\"34932944\", \"33881452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of PI3K that distinguish Trm establishment from Tfh programming not identified\", \"Whether ICOS limits VAT-Tregs through FOXO1–Klf2 axis specifically not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of TMD–Lck association, how ICOS signal strength is integrated across the PI3K and calcium arms to specify distinct T-cell fates (Tfh vs. Treg vs. Trm), and whether ICOS-dependent metabolic reprogramming is a general feature of its signaling or context-restricted.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of ICOS TMD–Lck interface\", \"Quantitative signaling model integrating PI3K and PLCγ1 arms absent\", \"Metabolic consequences of ICOS signaling tested only in collagen-induced arthritis model\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4, 23, 24, 25, 26]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 10, 11, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ICOSL\",\n      \"LCK\",\n      \"PIK3R1\",\n      \"FOXO1\",\n      \"NFATC2\",\n      \"RC3H1\",\n      \"NUFIP2\",\n      \"PELI1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nHmm, I need to double-check R-HSA-162582 — that's not in the allowed list. The correct Signal Transduction ID is R-HSA-162582. Let me check again... The allowed list says `R-HSA-162582  Signal Transduction`. Yes, that's correct.\n\nWait, actually looking more carefully at the allowed list: `R-HSA-162582  Signal Transduction`. But in the original list it's `R-HSA-162582`. Let me recheck the prompt... it says `R-HSA-162582  Signal Transduction`. Yes that's correct.\n\n```json\n{\n  \"mechanistic_narrative\": \"ICOS is an activation-induced T-cell co-stimulatory receptor that, through its exclusive ligand ICOSL (B7RP-1), drives germinal centre formation, T follicular helper (Tfh) cell differentiation and maintenance, regulatory T-cell IL-10 production, iNKT cell activation, and CD8+ tissue-resident memory T-cell establishment [PMID:9930702, PMID:11343123, PMID:25692700, PMID:34932944, PMID:18390727, PMID:22815292]. Structurally, ICOS binds ICOSL via a central FDPPPF motif and CC' loop with direct participation of an N110-linked glycan, and its transmembrane domain recruits Lck, which is required for p85/PI3K recruitment to the cytoplasmic tail; downstream PI3K–AKT signaling inactivates FOXO1 to suppress Klf2, establishing the Tfh homing receptor program, while a membrane-proximal cytoplasmic motif potentiates PLCγ1-dependent calcium flux and RhoA/Cdc42-mediated actin remodeling [PMID:33033255, PMID:30523347, PMID:12594849, PMID:25692700, PMID:25646266, PMID:27693916]. ICOS expression is transcriptionally controlled by Fyn–calcineurin–NFATc2 and MEK–ERK pathways and post-transcriptionally repressed by Roquin/NUFIP2-mediated mRNA decay targeting stem-loops in the ICOS 3′-UTR [PMID:16880206, PMID:29352114]. Homozygous ICOS deletion in humans causes common variable immunodeficiency characterized by defective B-cell class-switching and memory B-cell generation [PMID:12577056].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of ICOS as a novel activation-induced T-cell co-stimulatory receptor established that the CD28 superfamily contained a second, non-redundant co-stimulatory pathway with distinct cytokine output (IL-10 superinduction, no IL-2 upregulation).\",\n      \"evidence\": \"Molecular cloning, flow cytometry, functional co-stimulation assays, and immunohistochemistry of human tonsil T cells\",\n      \"pmids\": [\"9930702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity unknown at time of discovery\", \"Signaling pathway downstream of ICOS uncharacterized\", \"Tissue distribution beyond tonsil not fully mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery of B7RP-1/ICOSL as the exclusive ICOS ligand, and demonstration that ICOS–ICOSL and CD28–B7 systems do not cross-react, defined two parallel but independent co-stimulatory axes in adaptive immunity.\",\n      \"evidence\": \"Receptor–ligand binding assays and fusion-protein co-stimulation in murine system; additional biochemical characterization of human ICOS homodimer\",\n      \"pmids\": [\"10617205\", \"11169414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ligand specificity unknown\", \"ICOS–ICOSL affinity and kinetics not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"ICOS knockout mice revealed that ICOS is essential in vivo for germinal centre formation, Ig class switching, and T-dependent B-cell responses, while CTLA-4 was shown to antagonize ICOS-mediated cytokine production, establishing a co-stimulatory/co-inhibitory regulatory circuit.\",\n      \"evidence\": \"ICOS-deficient mouse phenotyping; anti-CTLA-4/anti-ICOS bead stimulation and IL-2 rescue experiments\",\n      \"pmids\": [\"11343123\", \"11290772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling intermediates not identified\", \"Mechanism of CTLA-4 suppression of ICOS expression unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Human ICOS deficiency was linked to common variable immunodeficiency, and ICOS signaling was shown to proceed through PI3K recruitment and MAP kinase activation, connecting receptor engagement to cytokine gene regulation.\",\n      \"evidence\": \"Homozygous ICOS deletion in patients with immunophenotyping; ICOS cross-linking with PI3K inhibitors and kinase assays in Th2 clones\",\n      \"pmids\": [\"12577056\", \"12594849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PI3K-binding motif on ICOS not mapped\", \"Transcription factors downstream of PI3K not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defining the Fyn–calcineurin–NFATc2 and MEK–ERK transcriptional circuits controlling ICOS promoter activity explained how TCR signal strength and co-stimulation regulate ICOS expression levels.\",\n      \"evidence\": \"ChIP of NFATc2 on icos promoter, luciferase reporters, Fyn−/− T cells, chemical inhibitors\",\n      \"pmids\": [\"16880206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin accessibility and epigenetic regulation of icos locus not addressed\", \"Post-transcriptional regulation not yet characterized\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Epistasis experiments placed ICOS upstream of CD40 and LTβR in germinal centre network formation, and demonstrated ICOS is required for iNKT cell homeostasis and effector function, broadening ICOS function beyond conventional T cells.\",\n      \"evidence\": \"ICOS−/− mice with agonistic anti-CD40 rescue; ICOS−/− and ICOSL−/− mice with α-GalCer challenge and adoptive iNKT transfer\",\n      \"pmids\": [\"18250437\", \"18390727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking ICOS to LTαβ induction on B cells not defined\", \"iNKT-intrinsic vs. extrinsic ICOS requirement not fully separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two-photon imaging showed ICOS drives T-cell pseudopod formation and persistent migration at the T–B border via bystander B-cell ICOSL, explaining how ICOS positions T cells for follicular entry independently of Bcl6; separately, ICOS was shown essential for Treg IL-10 production and suppressive function.\",\n      \"evidence\": \"Intravital two-photon microscopy with ICOS-deficient and ICOSL conditional-KO mice; ICOS−/− Treg transfer in airway tolerance and helminth models\",\n      \"pmids\": [\"23619696\", \"22815292\", \"23319295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoskeletal effectors downstream of ICOS mediating pseudopod formation not identified\", \"Whether ICOS-dependent Treg IL-10 operates through PI3K–FOXO1 untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic epistasis established that ICOS signals through PI3K to inactivate FOXO1, which in turn represses Klf2; Klf2 directly controls Tfh homing receptors (CXCR5, CCR7, PSGL1, S1PR1), providing a complete transcriptional pathway from receptor to cell positioning.\",\n      \"evidence\": \"Foxo1 conditional KO and nuclear-localization KI mice crossed to ICOS−/−; Klf2 ChIP on Tfh target promoters with ICOS blockade\",\n      \"pmids\": [\"25692700\", \"25646266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional transcription factors act in parallel with FOXO1 downstream of ICOS not tested\", \"Kinetics of FOXO1 inactivation upon ICOS ligation not measured\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A membrane-proximal cytoplasmic motif of ICOS was shown to potentiate calcium signaling via PLCγ1 activation and RhoA/Cdc42-dependent actin remodeling, revealing a PI3K-independent arm of ICOS signaling.\",\n      \"evidence\": \"ICOS cytoplasmic domain mutagenesis knock-in mice with calcium flux, PLCγ1 phosphorylation, and small GTPase activation assays\",\n      \"pmids\": [\"27693916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the adaptor linking the proximal motif to RhoA/Cdc42 unknown\", \"Relative contribution of calcium vs. PI3K arm to individual T-cell fates not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The ICOS transmembrane domain was identified as the site of Lck association prerequisite for p85/PI3K recruitment, resolving how ICOS activates PI3K; simultaneously, Roquin/NUFIP2-dependent mRNA decay targeting dual stem-loops in the ICOS 3′-UTR was established as the major post-transcriptional brake on ICOS levels, and Peli1 was identified as a transcriptional negative regulator via c-Rel.\",\n      \"evidence\": \"Domain-swap constructs with co-IP and in vivo Tfh/GC analysis; genome-wide RNAi screen with 3′-UTR mutagenesis; Peli1-KO mice with PI3K–AKT and Klf2 readouts\",\n      \"pmids\": [\"30523347\", \"29352114\", \"33707688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of TMD–Lck interaction unresolved\", \"How Roquin selects ICOS mRNA over other targets not fully elucidated\", \"Whether Peli1 directly ubiquitinates c-Rel to limit ICOS transcription not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The crystal structure of the ICOS–ICOSL complex at 3.3 Å revealed that the FDPPPF motif and CC' loop (with N110 glycan) mediate ligand specificity via a binding orientation distinct from CD28–B7, providing a structural rationale for the non-cross-reactivity of these pathways.\",\n      \"evidence\": \"X-ray crystallography at 3.3 Å with binding-assay validation\",\n      \"pmids\": [\"33033255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of full-length ICOS including TMD and cytoplasmic domain\", \"Dynamics of ICOS dimerization and its role in signaling complex assembly not characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ICOS–PI3K signaling in the tissue effector phase was shown to be required for establishment of CD8+ tissue-resident memory T cells independently of priming, expanding the functional repertoire of ICOS beyond CD4+ T-cell help; in a distinct context, ICOS–PI3K signaling was found to limit visceral adipose tissue Treg accumulation, revealing context-dependent effects on Treg biology.\",\n      \"evidence\": \"ICOS−/− and IcosYF/YF KI mice with adoptive transfer and temporal ICOSL blockade for Trm; same genetic models on high-fat diet for VAT-Treg analysis\",\n      \"pmids\": [\"34932944\", \"33881452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of PI3K that distinguish Trm establishment from Tfh programming not identified\", \"Whether ICOS limits VAT-Tregs through FOXO1–Klf2 axis specifically not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of TMD–Lck association, how ICOS signal strength is integrated across the PI3K and calcium arms to specify distinct T-cell fates (Tfh vs. Treg vs. Trm), and whether ICOS-dependent metabolic reprogramming is a general feature of its signaling or context-restricted.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of ICOS TMD–Lck interface\", \"Quantitative signaling model integrating PI3K and PLCγ1 arms absent\", \"Metabolic consequences of ICOS signaling tested only in collagen-induced arthritis model\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4, 23, 24, 25, 26]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 10, 11, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ICOSL\",\n      \"LCK\",\n      \"PIK3R1\",\n      \"FOXO1\",\n      \"NFATC2\",\n      \"RC3H1\",\n      \"NUFIP2\",\n      \"PELI1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}